

# Lawrence Berkeley National Laboratory

## Biological Systems & Engineering

### Title

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

### Permalink

<https://escholarship.org/uc/item/4j8893w1>

### Journal

Cell, 169(1)

### ISSN

0092-8674

### Authors

Baar, Marjolein P  
Brandt, Renata MC  
Putavet, Diana A  
et al.

### Publication Date

2017-03-01


### DOI

10.1016/j.cell.2017.02.031

Peer reviewed

# Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

## Graphical Abstract



## Authors

Marjolein P. Baar, Renata M.C. Brandt, Diana A. Putavet, ..., Jan H.J. Hoeijmakers, Judith Campisi, Peter L.J. de Keizer

## Correspondence

p.dekeizer@erasmusmc.nl

## In Brief

A FOXO4 peptide that selectively induces apoptosis of senescent cells reverses effects of chemotoxicity and aging in mice.

## Highlights

- A modified FOXO4-p53 interfering peptide causes p53 nuclear exclusion in senescent cells
- This FOXO4 peptide induces targeted apoptosis of senescent cells (TASC)
- TASC neutralizes murine liver chemotoxicity from doxorubicin treatment
- TASC restores fitness, hair density, and renal function in fast and naturally aged mice



# Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Marjolein P. Baar,<sup>1</sup> Renata M.C. Brandt,<sup>1</sup> Diana A. Putavet,<sup>1</sup> Julian D.D. Klein,<sup>1</sup> Kasper W.J. Derks,<sup>1</sup> Benjamin R.M. Bourgeois,<sup>7</sup> Sarah Stryeck,<sup>7</sup> Yvonne Rijkse,<sup>1</sup> Hester van Willigenburg,<sup>1</sup> Danny A. Feijtel,<sup>1</sup> Ingrid van der Pluijm,<sup>1,4</sup> Jeroen Essers,<sup>1,4,5</sup> Wiggert A. van Cappellen,<sup>2</sup> Wilfred F. van IJcken,<sup>3</sup> Adriaan B. Houtsmuller,<sup>2</sup> Joris Pothof,<sup>1</sup> Ron W.F. de Bruin,<sup>6</sup> Tobias Madl,<sup>7</sup> Jan H.J. Hoeijmakers,<sup>1</sup> Judith Campisi,<sup>8,9</sup> and Peter L.J. de Keizer<sup>1,8,10,\*</sup>

<sup>1</sup>Department of Molecular Genetics

<sup>2</sup>Erasmus Optical Imaging Center and Department of Pathology

<sup>3</sup>Department of Cell Biology

<sup>4</sup>Department of Vascular Surgery

<sup>5</sup>Department of Radiation Oncology

<sup>6</sup>Department of Surgery

Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3015CN, Rotterdam, the Netherlands

<sup>7</sup>Institute of Molecular Biology & Biochemistry, Center of Molecular Medicine, Medical University of Graz, 8010 Graz, Austria

<sup>8</sup>The Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA 94945, USA

<sup>9</sup>Lawrence Berkeley National Laboratories, Berkeley, CA 94720, USA

<sup>10</sup>Lead contact

\*Correspondence: [p.dekeizer@erasmusmc.nl](mailto:p.dekeizer@erasmusmc.nl)

<http://dx.doi.org/10.1016/j.cell.2017.02.031>

## SUMMARY

The accumulation of irreparable cellular damage restricts healthspan after acute stress or natural aging. Senescent cells are thought to impair tissue function, and their genetic clearance can delay features of aging. Identifying how senescent cells avoid apoptosis allows for the prospective design of anti-senescence compounds to address whether homeostasis can also be restored. Here, we identify FOXO4 as a pivot in senescent cell viability. We designed a FOXO4 peptide that perturbs the FOXO4 interaction with p53. In senescent cells, this selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis. Under conditions where it was well tolerated in vivo, this FOXO4 peptide neutralized doxorubicin-induced chemotoxicity. Moreover, it restored fitness, fur density, and renal function in both fast aging *Xpd*<sup>TTD/TTD</sup> and naturally aged mice. Thus, therapeutic targeting of senescent cells is feasible under conditions where loss of health has already occurred, and in doing so tissue homeostasis can effectively be restored.

## INTRODUCTION


Unresolved DNA damage can impair cellular function, promote disease development, and accelerate aging (López-Otín et al., 2013). To prevent such undesired consequences, cells are equipped with a range of DNA repair mechanisms (Hoeijmakers, 2009). However, these mechanisms are not flawless. When repair falls short, tissue integrity is still at least initially

maintained by independent stress-response mechanisms as apoptosis and cellular senescence (de Keizer, 2017). Senescent cells are permanently withdrawn from the cell cycle and generally develop a persistent pro-inflammatory phenotype, called the senescence-associated secretory phenotype (SASP) (Coppé et al., 2008). The SASP influences the cellular microenvironment, which can be beneficial early in life or in an acute setting of wound healing (Demaria et al., 2014; Muñoz-Espín et al., 2013). However, unlike apoptotic cells, which are permanently eliminated, senescent cells can prevail for prolonged periods of time and accumulate with age (Krishnamurthy et al., 2004). Because of their low but chronic SASP, persistent senescent cells are thought to accelerate aging and the onset of age-related diseases (de Keizer, 2017). Indeed, senescence has been associated with a plethora of (age-related) pathologies, and, conversely, genetic clearance of senescent cells can delay features of aging (Baker et al., 2016). It remains largely unclear how damaged cells avoid apoptosis in favor of senescence. We set out to address this question and to determine whether therapeutic targeting of senescent cells could not only delay but also counteract the loss of tissue homeostasis after acute damaging medical treatments, such as chemotherapy, or chronic damage caused either by accelerated or natural aging.

## RESULTS

### FOXO4 Is Elevated in Senescent Cells and Maintains Their Viability

To identify potential pivots in senescent cell viability, we initiated this study by investigating whether apoptosis-related pathways are altered in senescent cells. We performed unbiased RNA sequencing on samples of genomically stable primary human



**Figure 1. FOXO4 Is Elevated in Senescent Normal Fibroblasts and Ensures Their Viability**

(A) Schematic representation of the mRNA expression changes (Figure S1A) of the cell-intrinsic apoptosis pathway (Tait and Green, 2010) between senescent and control (proliferating) IMR90 fibroblasts. Inset: immunofluorescence for PUMA, BIM, and BCL2. (B) Volcano plot comparing transcriptional regulators in senescent versus control IMR90. (See Figure S1B for expression and *p* values). Dark blue: associated with apoptosis. Inset, left: RNA expression of the FOXO cluster. N.D. Not detectable. Right: protein levels of the FOXO cluster. FOXO1 was ectopically expressed as positive control.

(legend continued on next page)

IMR90 fibroblasts and IMR90 induced to senesce by ionizing radiation (IR) (Rodier et al., 2011). As senescent cells are reportedly apoptosis-resistant (Wang, 1995), we expected pro-apoptotic genes to be repressed. Surprisingly, however, senescent IMR90 showed an upregulation of prominent pro-apoptotic “initiators” PUMA and BIM while the anti-apoptotic “guardian” BCL-2 was reduced (Figures 1A and S1A). This suggested senescent IMR90 are primed to undergo apoptosis but that the execution of the death program is restrained. We reasoned such a brake could potentially be a transcriptional regulator and focused on transcription factors that have previously been linked to apoptosis, including STAT1, 2, and 4; RELB; NF $\kappa$ B; TP53; and FOXO4 (Figures 1B and S1B). Interference with JAK-STAT signaling is known not to affect the viability of senescent cells (Xu et al., 2015), and we have previously observed similar effects for NF $\kappa$ B and p53 inhibition (Freund et al., 2011; Rodier et al., 2009). Our interest was therefore directed to a factor that has not yet been studied as such, FOXO4 (Figure 1B). FOXO4 belongs to a larger mammalian family, with FOXO1 and 3 being its major siblings. FOXOs are well studied in aging and tissue homeostasis as targets of insulin/IGF signaling and as regulators of reactive oxygen species (de Keizer et al., 2011; Eijkelenboom and Burgering, 2013; Martins et al., 2016). Whereas senescence-inducing IR showed only mild effects on the expression of FOXO1 and 3, both FOXO4 mRNA and protein expression progressively increased (Figures 1C and 1D). We therefore wondered whether FOXO4 could function to balance senescence and apoptosis. We stably inhibited FOXO4 expression using lentiviral shRNA (Figure 1E). FOXO4 inhibition prior to senescence-induction resulted in a release of mitochondrial cytochrome C (Figure 1F) and BAX/BAK-dependent caspase-3 cleavage (Figure 1G). In addition, FOXO4 inhibition in cells that were already senescent, but not their control counterparts, reduced viability and cell density (Figures 1H and S1C). Together, these show that after acute damage FOXO4 favors senescence over apoptosis and maintains viability of senescent cells by repressing their apoptosis response.

#### FOXO4-DRI Disrupts PML/DNA-SCARS and Releases Active p53 in Senescent Cells

Interference with FOXO4 signaling could be a strategy to eliminate senescent cells and thereby potentially target senescence-related diseases. However, shRNA-mediated repression of FOXO4 would be complicated to translate to the clinic. Thus, we decided to design compounds that could structurally interfere with FOXO4 function instead. Immunofluorescence experiments showed FOXO4 to be gradually recruited to euchromatin foci after senescence-induction (Figures 2A–2C and S2A–2D). As senescence develops, promyelocytic leukemia (PML)

bodies fuse with 53BP1-containing DNA-SCARS to jointly regulate expression of the SASP (Rodier et al., 2011). High-resolution structured illumination microscopy (SIM) of nuclei of senescent cells showed FOXO4 to reside within these PML bodies, adjacent to 53BP1-containing DNA-SCARS (Figure 2D; Movies S1 and S2; Figures S2E–S2I).

p53 controls both apoptosis and senescence (Kruiswijk et al., 2015) and localizes to DNA-SCARS in senescent cells (Rodier et al., 2011). Under those conditions p53 is phosphorylated by ATM on Ser15, which blocks its MDM2-mediated degradation (Rodier et al., 2009). Consistent with the observation of FOXO4 residing in PML bodies, FOXO4 localized next to phosphorylated ATM substrates (Figure S2I) and pS15-phosphorylated p53 (Figure 2E). This raised the question whether FOXO4 could maintain senescent cell viability by binding p53 and inhibiting p53-mediated apoptosis in favor of cell-cycle arrest.

FOXOs can interact with p53, and the interaction domain has been characterized by nuclear magnetic resonance (NMR) (Wang et al., 2008). To interfere with the FOXO4-p53 interaction, we therefore designed a cell-permeable peptide comprising part of the p53-interaction domain in FOXO4 (Figures 2F and 2G). FOXO1 and FOXO3 are essential to numerous endogenous processes as development, differentiation, and tumor suppression, roles not prominently attributed to FOXO4 (Hosaka et al., 2004; Nakae et al., 2003; Paik et al., 2007; Renault et al., 2009). Another difference with FOXO1 and 3 is that FOXO4 is only marginally expressed in most tissues (Figures S2J and S2K), and FOXO4 knockout mice do not show a striking phenotype (Hosaka et al., 2004; Paik et al., 2007). We therefore chose a region in FOXO4 that is conserved in both humans and mice but differs from FOXO1 and FOXO3 (Figure S2L).

Research on peptide chemistry has shown that protein domains containing natural L-peptides can sometimes be mimicked by using D-amino acids in a retro-reversed sequence (Guichard et al., 1994). Modification of peptides to such a D-retro inverse (DRI)-isoform can render peptides new chemical properties, which may improve their potency in vitro and in vivo (Borsello et al., 2003). Several DRI-modified peptides have been shown to be well tolerated and therapeutically effective in clinical trials. These include a double-blinded, randomized, placebo-controlled Phase IIb trial (Beydoun et al., 2015; Deloche et al., 2014; Suckfuell et al., 2014) and a Phase I trial for systemic treatment of solid tumors (Warso et al., 2013), together showing there is precedence for DRI peptides in clinical therapy. This provided the rationale for designing the FOXO4 peptide in a DRI conformation, henceforth named FOXO4-DRI. We performed competition experiments by NMR to investigate whether FOXO4-DRI can inhibit the interaction between p53 and FOXO4 in vitro. Titration of a recombinant N-terminal domain of p53 (aa 1–312) to a solution containing the 1H, 15N-labeled FOXO4 Forkhead (FH)

(C) QPCR for changes in FOXO1, 3, and 4 mRNA after senescence-induction by 10 Gy IR. p21<sup>Cip1</sup> (biphasic increase), p53, and ETS2 (biphasic decrease) are included as controls.

(D) Immunoblot for changes in FOXO3 and 4 protein levels after senescence-induction by 10 Gy IR.


(E) The senescence-induced FOXO4 mRNA expression is successfully countered by two shRNAs.

(F) Cytochrome-C release assay (left) as measure for apoptosis in the conditions of (E), quantified in a histogram (right).

(G) Induction of cleaved caspase-3 after senescence induction in (mouse-specific) FOXO4-deprived wild-type or *bax/bak*<sup>-/-</sup> BMK cells.

(H) AqueousOne viability (left) and colony density (right; see also Figure S1C) of control and senescent IMR90 cells transduced with the short hairpins used in (E).





(legend on next page)

domain (aa 486–206) induced a progressive chemical shift perturbation (CSP) of <sup>1</sup>H, <sup>15</sup>N HSQC cross peaks, indicating specific binding of p53 to FOXO4 (Figure 2H). Stepwise addition of the FOXO4-DRI peptide to this complex caused the CSPs of FOXO4 to be reverted back to the unbound state, indicating FOXO4-DRI competes with FOXO4 for p53 binding in a dose-dependent manner and doing so with higher affinity (Figure 2I).

To facilitate cellular uptake of FOXO4-DRI, it was designed as a fusion with HIV-TAT, a basic and hydrophilic sequence that allows energy-independent cellular uptake of cargo through transient pore formation (Herce and Garcia, 2007). Using an antibody against HIV-TAT, we observed FOXO4-DRI to be taken up as soon as 2–4 hr after administration and to remain detectable for at least 72 hr (Figure 2J). Given that the affinity of antibodies is generally low, this indicates FOXO4-DRI effectively enters senescent cells at high intracellular concentrations, which remain abundant and stable over a prolonged period of time. Following its uptake, FOXO4-DRI reduced the number of senescence-induced FOXO4 foci, PML bodies, and 53BP1 DNA-SCARS while not affecting the number of small 53BP1 foci (Figure 2K).

FOXO4 can regulate expression of the p53-target p21<sup>Cip1</sup> in senescent cells (de Keizer et al., 2010), and through p21<sup>Cip1</sup>, p53 can induce p16<sup>In4a</sup>-independent cell cycle arrest in senescent cells (Di Leonardo et al., 1994). Moreover, p53 can induce apoptosis either through transactivating pro-apoptosis genes or in a transcription-independent manner by translocating to the mitochondria (Mihara et al., 2003). Examination of the promoter of Cdkn1a, the gene encoding p21<sup>Cip1</sup>, showed a canonical FOXO target sequence to be flanked by two p53 binding sites (Figure 2L). We therefore investigated the effect of FOXO4-DRI on p21<sup>Cip1</sup> and p53. FOXO4-DRI reduced senescence-associated p21<sup>Cip1</sup> levels (Figure 2L) and promoted the accumulation and nuclear exclusion of active pSer15-p53 (Figures 2M and S2M). Together, these results show that by competing with endogenous FOXO4 for p53 binding, FOXO4-DRI disrupts senescence-associated FOXO4/PML/DNA-SCARS and causes nuclear exclusion of active p53.


### FOXO4-DRI Can Selectively and Potently Target Senescent Cells for p53-Dependent Apoptosis

Given the reported pro-apoptotic role of active p53 when recruited to mitochondria, we next assessed the effects on senescent cell viability. Incubation of senescent and control IMR90 with increasing concentrations of FOXO4-DRI showed FOXO4-DRI to potently and selectively (11.73-fold difference) reduce the viability of senescent versus control IMR90 (Figure 3A) and other normal cells (Figure S3A). Real-time cell density measurements revealed the effect to occur as soon as 24–36 hr after administration (Figure 3B). Neither the same peptide in L-isoform (Figure 3C) nor an unrelated DRI-peptide based on a distinct Forkhead protein, FOXM1 (Kruiswijk et al., 2016), affected senescent cell viability (Figure 3D). These results show that FOXO4-DRI can target senescent cells, and they highlight the importance of the DRI-modification for its potency.

Two classes of anti-senescence compounds have been reported so far: Quercetin/Dasatinib, either alone or in combination (Zhu et al., 2015), and the pan-BCL inhibitors ABT-263/737 (Chang et al., 2016; Yosef et al., 2016). Quercetin and Dasatinib have been reported to be non-specific (Chang et al., 2016). We found no selectivity toward senescent IMR90 (Figure S3B), and therefore this cocktail was not explored further. ABT-263 (Chang et al., 2016) and ABT-737 (Yosef et al., 2016) target the BCL-2/W/XL family of anti-apoptotic guardians (see also Figure 1A). Indeed, ABT-737 showed selectivity for senescent IMR90 (Figure S3B). However, already at low doses, it appeared to influence control cells as well (Figure S3B). Also in a treatment regimen where both compounds were added in consecutive rounds of lower concentrations, FOXO4-DRI proved to be selective against senescence yet safe to normal cells (Figures 3E and S3C).

We next addressed the role of p53 in FOXO4-DRI-mediated clearance of senescent cells. Stable knockdown of p53 reduced the ability of FOXO4-DRI to target senescent IMR90 (Figures 3F and S3D). A similar effect was observed when the senescent cells were co-incubated with the pan-caspase inhibitors QVD-OPH or ZVAD-FMK (Figure 3G), suggesting a caspase-dependent effect.

**Figure 2. FOXO4 Localizes to Senescence-Associated PML/DNA-SCARS, which Contain Active p53 and Can Be Disrupted by FOXO4-DRI**  
 (A) FOXO4 foci and senescence-associated heterochromatin structures in senescent IMR90 (see also Figures S2A–S1). Bottom: intensity plot (arbitrary units) of individual pixels measured by the indicated line.  
 (B) Quantification of cells containing  $\geq 3$  FOXO4 foci in time after senescence-inducing IR.  
 (C) FOXO4 foci in senescent cells transduced with the shRNAs against FOXO4 described in Figure 1E.  
 (D) Structured illumination microscopic (SIM) image of the nucleus of a senescent IMR90 cell stained for FOXO4, 53BP1, and PML. Yellow arrow: Area processed for 3D surface-rendering (insets).  
 (E) FOXO4 and Ser15-phosphorylated p53, assessed as in (A). Note that for FOXO4 a different antibody (Sigma) was used.  
 (F and G) Sequence (H indicates predicted helix) and 3D structure of FOXO4 used for the design of FOXO4-DRI. The amino acids indicated in yellow in (F) are shown as yellow spheres in the displayed structure of FOXO4 (3L2C, protein databank). Green aa in (F) are not visualized in this 3D structure but are part of the FOXO4-DRI sequence. Red aa in (G) change most upon p53-interaction (Wang et al., 2008). See also Figures S2J–S2L.  
 (H) <sup>1</sup>H, <sup>15</sup>N HSQC NMR spectrum of <sup>15</sup>N-labeled recombinant FOXO4<sup>86–206</sup> incubated with increasing stoichiometric equivalents of recombinant p53 (60, 120, 240, or 300  $\mu$ M, respectively).  
 (I) Experiment as in (H), but with one times or two times stoichiometric equivalents of FOXO4-DRI (300 or 600  $\mu$ M, respectively).  
 (J) Cellular uptake of FOXO4-DRI in senescent IMR90 visualized by an antibody against the HIV-TAT sequence.  
 (K) Quantification of the number of FOXO4/PML/53BP1-DNA-SCARS in control and senescent IMR90 incubated 3 days with 25  $\mu$ M FOXO4-DRI and the pan caspase-inhibitor QVD-OPH. Number of small 53BP1 foci shown as control. Only infrequently FOXO4 foci were visible in control cells.  
 (L) Schematic representation of the p21<sup>Cip1</sup> (CDKN1a) promoter in which the canonical FOXO target sequence is flanked by two p53 binding sites.  
 (M and N) Quantification of nuclear p21<sup>Cip1</sup> intensity of senescent IMR90 treated as in (K). (N) Left: Immunoblot of senescent IMR90 cells incubated for the indicated time points with FOXO4-DRI and processed for Ser15-phosphorylated and total p53. Middle: Nuclear exclusion of pSer15-p53 in cell treated as in (K and M). Right: Quantification of pSer15-p53 foci per nucleus of senescent IMR90.



**Figure 3. FOXO4-DRI Selectively Eliminates Senescent Cells through p53-Mediated Cell-Intrinsic Apoptosis**

(A) Viability assay of senescent and control IMR90 incubated with increasing doses of FOXO4-DRI ( $\mu\text{M}$ ). The selectivity index (SI<sub>50</sub>) reflects the differences in EC<sub>50</sub> of a non-regression analysis for both groups. See also [Figure S3A](#).

(B) Real-time cell density measurement by xCELLigence of control and senescent IMR90 incubated with or without FOXO4-DRI (25  $\mu\text{M}$ ).

(C) Viability assay comparing the effects of increasing doses of FOXO4-DRI and the same peptide in L-isomer, FOXO4-L.

(D) Viability assay comparing FOXO4-DRI, FOXO4-L, and an unrelated FOXM1-DRI peptide ([Kruiswijk et al., 2016](#)), at 6.25, 12.5, and 25  $\mu\text{M}$ , respectively.

(E) Viability assay comparing the pan-BCL inhibitor ABT-737 to FOXO4-DRI, when applied in three consecutive rounds at 1/3 the final concentration each (see also [Figures S3B](#) and [S3C](#)). SI<sub>75</sub> reflects differences in EC<sub>75</sub> of a non-regression analysis for both groups.

(F) Viability assay comparing the effect of FOXO4-DRI on cells depleted for p53 by shRNA. See [Figure S3D](#) for effects on p53 expression.


(G) Viability assay comparing the effect of FOXO4-DRI senescent cells incubated with pan-caspase inhibitors (20  $\mu\text{M}$ ).

(H) Representative still images of real-time confocal-based imaging of senescent and control cells in the presence of a caspase-3/7 activatable dye (green) and incubated with FOXO4-DRI. See also [Movies S3](#) and [S4](#). Imaging started 8 hr after FOXO4-DRI addition.

Indeed, real-time imaging in the presence of a caspase-3/7-activatable dye showed FOXO4-DRI to specifically induce caspase-3/7 activation in senescent, but not control, cells ([Figure 3H](#);

[Movies S3](#) and [S4](#)). Together, these data show that FOXO4-DRI potently and selectively reduces the viability of senescent cells by competing with FOXO4-p53 binding, thereby triggering





(legend on next page)

release of active p53 to the cytosol and inducing cell-intrinsic apoptosis through caspase-3/7. This establishes FOXO4-DRI as a genuine inducer of TASC. (targeted apoptosis of senescent cells).

### FOXO4-DRI Counteracts Chemotherapy-Induced Senescence and Loss of Liver Function

Given the potency of FOXO4-DRI against senescence *in vitro*, we wondered whether FOXO4-DRI could be of therapeutic use against senescence-related pathologies. We therefore employed three independent *in vivo* senescence models, one for chemotoxicity (Figure 4), one for accelerated aging (Figures 5 and 6), and one for natural aging (Figure 7). In all of these, we made use of the recently developed senescence-detection system: p16::3MR. In this system the promoter of the major senescence gene p16<sup>ink4a</sup> drives expression of Renilla luciferase (RLUC) to allow longitudinal visualization of senescence. In addition, it expresses a thymidine kinase (TK) from the herpes simplex virus, which induces apoptosis when cells are presented with its substrate ganciclovir (GCV) (Figure S4A; Demaria et al., 2014).

Off-target toxicity limits the maximum tolerated dose of chemotherapeutic drugs and causes long term health problems in cancer survivors, including an acceleration of aging (Henderson et al., 2014). Chemotherapy can induce senescence (Ewald et al., 2010), and we therefore determined whether therapeutic removal of senescence could influence chemotoxicity. As an example, we used the common chemotherapeutic drug doxorubicin, which can indeed induce senescence (Cahu et al., 2012; Roninson, 2003) and liver toxicity in rodents and humans (Damodar et al., 2014). In agreement with these reports, doxorubicin induced senescence in IMR90 *in vitro*, evident by elevated SA- $\beta$ -GAL activity, expression of p16<sup>ink4a</sup>, and the early and late SASP factors IL-1 $\alpha$  and IL-6 (Orjalo et al., 2009), respectively (Figures 4A–4C and S4B). As seen for IR-senescent cells (Figures 2 and 3), doxorubicin-induced senescent cells showed an upregulation in FOXO4 foci (Figures 4B and 4C) and FOXO4-DRI potently and selectively lowered the viability of doxorubicin-senescent versus control IMR90 (Figure 4D). In line with the IR-senescence data, low effective doses of FOXO4-DRI were well tolerated in normal IMR90 compared to ABT-737 while being


very potent against doxorubicin-senescent cells at higher doses (Figure 4E). Also in this setting, the potency of FOXO4-DRI was more pronounced when applied in consecutive rounds (Figures 4F and S4C).

It could be that FOXO4-DRI merely lowers the threshold for cells to enter apoptosis after DNA damage. This would impair its potential for *in vivo* or clinical translation. Incubation of normal IMR90 with FOXO4-DRI, administered at various time-points prior to doxorubicin exposure, did not influence the sensitivity of cells to doxorubicin (Figure 4G). In contrast, doxorubicin-senescent cells were effectively cleared. Thus, FOXO4-DRI does not predispose healthy cells to DNA damage, but selectively targets cells that have undergone senescence as a consequence of earlier doxorubicin exposure. Together this prompted us to try a similar sequential treatment regimen of FOXO4-DRI in doxorubicin-exposed mice *in vivo*.

In follow-up of the *in vitro* data, doxorubicin progressively induced senescence *in vivo* as detected by p16<sup>ink4a</sup>-driven RLUC in p16::3MR mice (Figure S4D). Furthermore, as seen in patients, doxorubicin reduced total body weight (Figure 4J) and induced expression of FOXO4 foci and IL-6 in the liver (Figures 4K and 4L). Strikingly, these effects were neutralized after sequential treatment with FOXO4-DRI (Figures 4H–4L). We therefore wondered whether liver function was also affected. Doxorubicin strongly induces plasma levels of aspartate aminotransferase (AST), an established indicator of liver damage (Damodar et al., 2014) (Figure 4M). Excitingly, FOXO4-DRI potently counteracted the doxorubicin-induced increase in plasma AST (Figure 4N). To address whether these effects are mediated through clearance of senescence, we combined treatment of FOXO4-DRI with GCV to facilitate senescence clearance through the TK suicide gene of p16::3MR construct. GCV reduced doxorubicin-induced p16-RLUC expression (Figure S4E) and plasma AST levels (Figures 4M and S4F), indicating AST reduction is indeed caused by clearance of senescent cells. In both cases FOXO4-DRI did not further enhance these effects. Together, these data indicate that FOXO4-DRI is effective in reducing doxorubicin-induced senescence *in vitro* and *in vivo* and in doing so neutralizes the doxorubicin-induced loss in body weight and liver toxicity. Thus, FOXO4-DRI is effective against chemotoxicity.

### Figure 4. FOXO4-DRI Counteracts Doxorubicin-Induced Senescence and Chemotoxicity *In Vivo*

- (A) SA- $\beta$ -GAL assay to detect senescence in IMR90 7 days after treatment two times (1 day in between) with 0.1  $\mu$ M doxorubicin.  
 (B) Immunofluorescence for p16<sup>ink4a</sup> and FOXO4 in control or Doxo-senescent IMR90. See also Figure S4B.  
 (C) Quantification of the % of cells positive for p16<sup>ink4a</sup>, IL1 $\alpha$ , IL6, and FOXO4 foci after doxorubicin-induced senescence.  
 (D) Viability assay comparing the effect of FOXO4-DRI on control and Doxo-senescent cells *in vitro*. SI determined as in Figure 3A.  
 (E) Viability assay comparing ABT-737 versus FOXO4-DRI on Doxo-senescent cells.  
 (F) Same as in (E), but both added three times at 1/3 the final concentration. See also Figure S4C.  
 (G) Viability assay comparing effects of incubation of FOXO4-DRI for various time points prior, during, or after doxorubicin exposure (blue line) versus cells already induced to senesce by doxorubicin (green boxes). M = Mock.  
 (H) Representative bioluminescence image and quantification of p16-driven senescence (RLUC) in p16::3MR mice (see Figures S4A and S4D), treated as indicated with doxorubicin, followed by FOXO4-DRI or Mock.  
 (I) Timeline of experiments in (J–N). Doxorubicin: two times *i.p.* at 10 mg/kg. FOXO4-DRI: the times IV at 5 mg/kg, every other day (day 1, 3, and 5).  
 (J) Quantification of the % change in body weight of doxorubicin-exposed mice treated with FOXO4-DRI or PBS, respectively.  
 (K) Quantification of the number of liver cells with  $\geq 10$  FOXO4 foci after doxorubicin-exposure and treatment with PBS or FOXO4-DRI.  
 (L) Visualization and quantification of the % of liver cells from the mice in (K) expressing IL-6.  
 (M) Quantification of the doxorubicin-induced increase in plasma AST levels as marker for liver damage.  
 (N) Quantification of the effects of PBS or FOXO4-DRI on doxorubicin-induced plasma levels of AST and urea as markers for liver and kidney damage, respectively. See also Figures S4E and S4F.




**Figure 5. FOXO4-DRI Decreases Senescence and Counters Features of Frailty in Fast-Aging *Xpd*<sup>TTD/TTD</sup> Mice**

(A) Representative mice and quantification of p16<sup>ink4a</sup>-driven RLUC Radiance in 26-week-young wild-type and *Xpd*<sup>TTD/TTD</sup> mice crossed into p16::3MR. (B) Left: timeline for visualization of effects of FOXO4-DRI or PBS on p16-driven senescence by bioluminescence in *Xpd*<sup>TTD/TTD</sup>. Middle: representative visualization of p16<sup>ink4a</sup>-driven senescence in the same *Xpd*<sup>TTD/TTD</sup>-p16::3MR mouse before and after FOXO4-DRI. Right: quantification of the effects of FOXO4-DRI or PBS on senescence in a larger cohort of *Xpd*<sup>TTD/TTD</sup>-p16::3MR mice. (C) Timeline for measuring the effects of FOXO4-DRI or PBS on hair density, behavior, and running wheel activity in (D–I). (D) FOXO4-DRI improves fur appearance of *Xpd*<sup>TTD/TTD</sup> mice. Left panels: representative images of the same *Xpd*<sup>TTD/TTD</sup> animal before and after treatment with FOXO4-DRI. Right panel: quantification of the average change in fur score (See also Figure S5A). (E) Quantification of abdominal temperature measured by infrared thermometer as measure for fur density of WT versus *Xpd*<sup>TTD/TTD</sup> mice (left) and the effects of FOXO4-DRI and PBS in the mice from (D) and Figure S5A (right). (F) Quantification of the response of the *Xpd*<sup>TTD/TTD</sup> mice from (D) to gentle physical stimuli before and after treatment with FOXO4-DRI or PBS. Note that *Xpd*<sup>TTD/TTD</sup> mice are generally relatively non-responsive. See also Figure S5B. (G) Quantification of the average distance run per day of WT versus *Xpd*<sup>TTD/TTD</sup>. (H) Example of changes in running wheel behavior of a WT versus *Xpd*<sup>TTD/TTD</sup> mouse treated with FOXO4-DRI. Data normalized to 100% for respective running wheel activity at baseline. On day 10 a blood sample was taken, resulting in a transient decrease in activity. (I) Quantification of the average change in running wheel activity in wild-type and *Xpd*<sup>TTD/TTD</sup> mice after PBS or FOXO4-DRI treatment.

**FOXO4-DRI Counteracts Senescence and Features of Frailty in Fast-Aging *Xpd*<sup>TTD/TTD</sup> Mice**

We next wondered whether FOXO4-DRI could influence the healthspan of mice in which senescence and the concomitant

loss of tissue homeostasis were not actively induced but were allowed to develop spontaneously as a consequence of aging. As is the case for humans (Ferrucci et al., 2005), we expected strong biological variation in senescence and the SASP in naturally



**Figure 6. By Targeting Senescence, FOXO4-DRI Counters Loss of Renal Function of *Xpd*<sup>TTD/TTD</sup> Mice**

(A) Quantification of renal filtering capacity measured by plasma [urea] in 13-, 26-, and 130-week-old wild-type mice and 13- and 26-week *Xpd*<sup>TTD/TTD</sup> mice.  
 (B–D) Visualization of senescence (SA-β-GAL), the major SASP factor IL-6 and FOXO4 foci in 26-week- and 130-week-wild-type and 26-week *Xpd*<sup>TTD/TTD</sup> old kidneys. Tubuli (T), Glomeruli (G). Inset (C): magnification of SA-β-GAL to reveal affected areas. Inset (D): quantification of the % of renal cells expressing ≥ 10 FOXO4 foci.  
 (E) TUNEL assay to detect apoptosis in kidney sections of 130-week-old WT mice treated 3 days with PBS or FOXO4-DRI. See Figure S6A–S6D for pipeline and results with shFOXO4.  
 (F) Quantification of the % of platelets at time of sacrifice versus baseline for WT and *Xpd*<sup>TTD/TTD</sup> mice treated with PBS or FOXO4-DRI. See also Figure S6E.  
 (G) Representative images of kidneys from 26-week WT or *Xpd*<sup>TTD/TTD</sup> mice stained for LMNB1 loss. Quantified are the average number of nuclei per kidney positive for LMNB1 (at least 400 nuclei per mouse).  
 (H) Viability assay on control or senescent IMR90 incubated with recombinant IL1α, IL1β, or IL1 receptor antagonist (IL1-RA) 24 hr prior to exposure of FOXO4-DRI.  
 (I) Viability curves for control or senescent IMR90 incubated with recombinant IL1α, IL1β, or IL1 receptor antagonist (IL1-RA) 24 hr prior to exposure of FOXO4-DRI.  
 (J) Representative images of kidneys from 26-week WT or *Xpd*<sup>TTD/TTD</sup> mice stained for IL-6. Quantified are the average number of IL-6 positive nuclei per kidney (at least 400 nuclei per mouse).  
 (K) Quantification of plasma [urea] in 13-, 26-, and 130-week-old wild-type mice and 13- and 26-week *Xpd*<sup>TTD/TTD</sup> mice.  
 (L) Quantification of plasma [urea] in 130-week-old *Xpd*<sup>TTD/TTD</sup> mice treated with PBS or FOXO4-DRI 3 days prior to i.p. injection.

(legend continued on next page)



aged wild-type mice. To reduce the effects of biological noise, we therefore decided to first employ fast-aging mice. We sought a model that recapitulates features of natural aging and does not suffer from age-related pathologies caused by other processes such as apoptosis (de Keizer, 2017). This we found in  $Xpd^{TTD/TTD}$ , a model based on the human premature-aging syndrome trichothiodystrophy (TTD) (de Boer et al., 2002; de Boer et al., 1998). Using the p16::3MR reporter system, we observed that already at a young age  $Xpd^{TTD/TTD}$  animals show high levels of p16-positive senescence (Figure 5A). As also seen for doxorubicin-induced senescence, FOXO4-DRI reduced this effect (Figure 5B); this result indicates that  $Xpd^{TTD/TTD}$  is a valid fast-aging model for studying the effects of FOXO4-DRI on spontaneously developed senescence in vivo.

Underscoring their aging phenotype,  $Xpd^{TTD/TTD}$  mice show accelerated loss of hair (Figure 5D; de Boer et al., 1998). While not initially focused on this phenotype, we observed a robust improvement of fur density in FOXO4-DRI-treated  $Xpd^{TTD/TTD}$  mice (Figures 5C and 5D and S5A). To address this more quantitatively, we determined the infrared-measured abdominal surface temperature of the mice. Due to the lack of fur, the abdominal temperature of  $Xpd^{TTD/TTD}$  mice was several degrees higher than wild-type counterparts, an effect reduced by FOXO4-DRI (Figure 5E). A second unexpected observation was found in the behavior of the treated mice. Whereas  $Xpd^{TTD/TTD}$  mice generally show less exploratory behavior compared to wild-type littermates, FOXO4-DRI-treated animals were noticeably more active (Figure S5B). To also investigate this more quantitatively, we scored the responsiveness of the mice to gentle physical stimuli. Despite individual variation,  $Xpd^{TTD/TTD}$  mice were on average considerably more responsive to such stimuli after FOXO4-DRI treatment (Figure 5F). Finally, as a more objective measure of activity, we tracked voluntary physical activity in a set-up in which the mice were continuously housed in cages with free access to running wheels. Despite significant individual differences,  $Xpd^{TTD/TTD}$  mice were found to run  $1.37 \pm 0.54$  km/day on average, compared to  $9.37 \pm 1.1$  km/day seen for wild-type mice, arguing they are indeed less mobile (Figure 5G). In line with the behavioral results, exposure of the mice to FOXO4-DRI increased running wheel activity over time in the majority of these (Figures 5H and 5I). Together, these results indicate that FOXO4-DRI can reduce cellular senescence and counteract hair loss and general frailty in fast-aging  $Xpd^{TTD/TTD}$  mice.

### FOXO4-DRI Counteracts Loss of Renal Function in Fast-Aging $Xpd^{TTD/TTD}$ Mice

The phenotypical and behavioral results described above are difficult to connect to a molecular mechanism. We therefore decided to focus on the role of senescence in aging-induced

decline in function of specific tissues. Pilot measurements of various metabolites in plasma samples of  $Xpd^{TTD/TTD}$  mice suggested they suffer from decreased renal function. As injected compounds tend to accumulate in the kidney, these together argued for investigating the potential of therapeutic removal of senescence in this organ. Urea is secreted through urine but becomes detectable in the blood when glomerular filtration rates drop. Plasma urea is therefore a marker of declined renal filtering capacity (Gowda et al., 2010; Lyman, 1986). In fact, it was recently established that semigenetic clearance of senescence can delay the aging-induced increase in plasma urea, establishing senescence as a culprit for loss of renal filtering capacity during aging (Baker et al., 2016). As evident from the increase in plasma urea levels, renal function indeed declines in wild-type mice as they age (Figure 6A; 26 weeks versus 130 weeks). This was faithfully recapitulated early in life in  $Xpd^{TTD/TTD}$  mice (Figure 6A; 26 weeks WT versus 26 weeks TTD). Both naturally aged wild-type and young  $Xpd^{TTD/TTD}$  kidneys showed a strong increase in SA- $\beta$ -GAL activity and IL-6 expression in the tubular regions (Figures 6B and 6C). In addition, they also showed a significant increase in tubular cells positive for FOXO4 foci (Figure 6D), together indicating that both modes show elevated senescence. Using an ex vivo system of aged kidney slices, FOXO4-DRI induced strong terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positivity within 3 days (Figures 6E and S6A–S6D), indicating that FOXO4-DRI can also induce apoptosis in these cells. Altogether this provided rationale for investigating the potency of FOXO4-DRI on tubular senescence and renal function in vivo.

A limitation to the therapeutic potential of the senolytic pan-BCL inhibitors ABT-263/ABT-737 is their tendency to cause severe thrombocytopenia (Schoenwaelder et al., 2011). This is undesirable when actually aiming to restore healthspan of aged individuals. Comparing platelet levels before and 30 days after treatment showed FOXO4-DRI not to noticeably influence platelet levels (Figure 6F) or other whole blood values (Figure S6E). Neither did it cause deleterious effects on non-proliferative tissues as far as tested, e.g., the heart (Figure S6F). Encouraged by the passing of at least these initial safety concerns, we progressed to measuring the effects of FOXO4-DRI on renal senescence and functional capacity. In line with the SA- $\beta$ -GAL data, tubuli of  $Xpd^{TTD/TTD}$  kidneys show severe loss of LMNB1 (Figure 6G), a robust molecular marker of senescence (Freund et al., 2012). This is paralleled with elevated IL-6 (e.g., Figure 6J), indicative of SASP, and elevated urea levels in the blood (e.g., Figure 6K). SASP factors as IL-6 may be the cause for the observed loss in renal function, and we wondered how FOXO4-DRI would function under such high-SASP conditions. In vitro experiments showed FOXO4-DRI to be more potent against senescent cells in which SASP was


(I) Viability plot showing the effect of FOXO4-DRI on control and senescent IMR90 pretreated with cortisol and LPS, prior to FOXO4-DRI treatment.

(J) Staining as in (G), but for the SASP marker IL-6. Quantified is the average IL-6 intensity per kidney over at least three frames per mouse for at least four mice per group.

(K) Quantification of the % plasma [urea] of three pooled cohorts of WT and  $Xpd^{TTD/TTD}$  mice ( $n = 7-8$  mice/treatment) after 30-day treatment with PBS or FOXO4-DRI. Data are represented as mean  $\pm$  SEM. See also Figure S4G.

(L) Experiment as in (K), but using ganciclovir (GCV) to mediate semigenetic clearance of senescent cells through the thymidine kinase expressed by the p16::3MR construct. As GCV is i.p. administered, also FOXO4-DRI was i.p. administered in this experiment.





**Figure 7. By Targeting Senescence, FOXO4-DRI Counters Frailty and Loss of Renal Function in Naturally Aged p16::3MR Mice**

(A) Quantification of p16<sup>ink4a</sup>-driven RLUC radiance in 104-week-old p16::3MR mice compared to 26-week counterparts. Note there is a larger degree of spread in the signal, suggesting biological variation.

(B) Quantification of the % platelets at time of sacrifice/baseline of naturally aged p16::3MR mice treated with PBS or FOXO4-DRI for 30 days. Procedure as in Figure 5C.

(C) Representative images and quantification of p16<sup>ink4a</sup>-driven RLUC radiance of mice from (B).

(D) Example of fur density in FOXO4-DRI versus Mock-treated male p16::3MR mice. See also Figure S7B.

(E) Quantification of the responsiveness of the mice in (B–D) treated with FOXO4-DRI or PBS. Analysis as in Figure 5F.

(F–I) Quantification of the effects of FOXO4-DRI on LMNB1 loss and IL6 intensity in the kidneys and plasma [urea] and [creatinine] of the naturally aged p16::3MR mice from (B). (G) Quantification of % plasma [urea] and [creatinine] of naturally aged (110+ weeks) p16::3MR mice at 30 days after i.p. injection with three times 5 mg/kg (every other day) FOXO4-DRI or five times 25 mg/kg/day with GCV to clear senescent cells semigenetically.

transiently boosted by recombinant IL1 $\alpha$ / $\beta$  or lipopolysaccharide (LPS), whereas an IL1 receptor antagonist or the general anti-inflammatory drug cortisol reduced its potency (Figures 6H and 6I). Thus, FOXO4-DRI actually is most effective against senescent cells expressing high levels of SASP and could as such be particularly effective against loss of renal function. Excitingly, while not substantially influencing total body nor kidney weight (Figure S6G), FOXO4-DRI treatment normalized the percentage of tubular cells lacking LMNB1 (Figure 6G), the tubular IL-6 elevation (Figure 6J), and the elevations in plasma urea levels (Figure 6K). To address whether this is mediated by senescence clearance, we again made use of the ability of the 3MR construct to eliminate senescent cells through GCV. As GCV is typically administered i.p., we treated a cohort of *Xpd*<sup>TTD/TTD</sup>-p16::3MR mice i.p. with FOXO4-DRI and GCV.

GVC and FOXO4-DRI induced a comparable reduction in plasma urea in both groups (Figure 6L). Thus, FOXO4-DRI targets high SASP-expressing senescent cells that have naturally developed in the kidneys of fast-aging *Xpd*<sup>TTD/TTD</sup> mice and in doing so restores kidney homeostasis.

#### FOXO4-DRI Counteracts Frailty and Loss of Renal Function in Naturally Aged Mice

Encouraged by these results, we decided to challenge whether FOXO4-DRI could also target senescence and tissue homeostasis in normal mice that were allowed to age naturally. As expected, the biological variation in p16-driven senescence was substantial in aged p16::3MR, compared to young *Xpd*<sup>TTD/TTD</sup>-p16::3MR (Figures 7A and 7C). The variation in running wheel activity was too large to perform meaningful experiments

(Figure S7A). Nonetheless, while again not influencing platelet levels (Figure 7B), FOXO4-DRI significantly reduced p16-driven RLUC (Figure 7C) and could improve fur density (Figure 7D) and responsiveness (Figure 7E). Furthermore, in the kidneys of these mice, FOXO4-DRI increased the number of LMNB1 positive cells (Figure 7F), reduced IL-6 expression (Figure 7G), and restored renal filtering capacity measured by decreased plasma urea (Figure 7H). As an extra control, the plasma levels of a second metabolite indicative of reduced renal function, creatinine, were measured. This also was reduced by FOXO4-DRI, independently confirming the beneficial effect of FOXO4-DRI on the restoration of renal filtering capacity in naturally aged mice (Figure 7I). As seen for the *Xpd<sup>TTD/TTD</sup>-p16::3MR* mice, i.p. administration of FOXO4-DRI or GCV equally reduced plasma urea and creatinine levels (Figure 7J). Thus, senescent cells are causal for the reduction in renal function in fast-aging *Xpd<sup>TTD/TTD</sup>* and naturally aged wild-type mice, and by selective targeting of high-SASP expressing senescent cells in the tubuli, FOXO4-DRI can restore kidney homeostasis. By inducing TASC, FOXO4-DRI may thus be a potent drug to restore loss of health after natural aging and is an attractive option to explore further in the battle against those age-related diseases that are at least in part driven by senescence.

## DISCUSSION

With life expectancy projected to increase in the foreseeable future (Vaupel, 2010), it is important to develop strategies to extend and restore healthspan. Cell-penetrating peptides (CPPs) are relatively understudied in aging research. Further analysis of their use is warranted as they serve several major advantages. Counter to broad-range inhibitors, CPPs can in theory target any surface-exposed stretch of amino acids to block specific protein-protein interactions and, in doing so, they can selectively modulate very specific downstream signaling events (discussed in de Keizer (2017)). Other compounds, classified as senolytics, have been described to influence senescent cell viability. As a CPP, FOXO4-DRI differs from these by being designed around a specific amino acid sequence in a molecular target only mildly expressed in most normal tissues (see e.g., Figures S2J and S2K). Though a more thorough analysis is required, at least as far as tested here FOXO4-DRI appears to be well tolerated, which is an absolutely critical milestone to pass when aiming to treat relatively healthy aged individuals (de Keizer, 2017).

FOXO4-DRI effectively disrupts the p53-FOXO4 interaction (Figures 2H and 2I), but the importance of the FOXO4 protein itself is more complicated in DNA damage and senescence. As FOXO4-DRI causes nuclear exclusion of active p53, the levels of p21<sup>Cip1</sup> decline (Figures 2L–2N). However, the loss of p21<sup>Cip1</sup> alone is insufficient to induce apoptosis and was actually shown to induce a senescence-escape instead (Brown et al., 1997). Rather, the exclusion of p53 itself has been reported to induce apoptosis directly when relocated to mitochondria (Mihara et al., 2003), thereby explaining the FOXO4-DRI effects. FOXO4 shRNAs induce apoptosis in senescent IMR90 (Figures 1E–1H), arguing that full FOXO4 inhibition might also be of use against senescence. True as this may be, chronic FOXO4 reduc-

tion is not advisable as FOXOs play a role in DNA-damage repair and *Foxo4<sup>-/-</sup>* mice are susceptible to acute damage (Zhou et al., 2009). In contrast to loss of FOXO4, FOXO4-DRI does not sensitize healthy cells to acute DNA damage (Figure 4G). Thus, while permanent FOXO4 inhibition is inapplicable, the fact that as a CPP it can block a specific protein-protein interaction makes FOXO4-DRI selective and thereby well tolerated and effective.

Based on these positive effects, it is now possible to envision a point on the horizon where the disease indications are identified that could benefit most from FOXO4-DRI therapy. High SASP-secreting cells are likely to play a much larger role in disease development than more sterile senescent cells. Through SASP, senescent cells may permanently confer a state of stemness in neighboring cells and thereby impair tissue function and renewal, an effect that we recently described in the senescence-stem lock model for aging (de Keizer, 2017). FOXO4-DRI has a strong preference for targeting high-SASP subpopulations of senescent cells, but it is unclear what causes heterogeneity in the SASP. It will be a major achievement to unravel those mechanisms and to steer these such that therapeutic targeting is most beneficial. In that sense, identification of senescence-driven pathologies that rely on SASP may help in optimizing candidates for therapy. *Xpd<sup>TTD/TTD</sup>* is a pleiotropic model for aging that can be effectively used as a basis for such research. It is a well-established model for osteoarthritis, especially in cohorts of older age than we used here (52 weeks) (Botter et al., 2011) and for the unhealthy loss in muscle (sarcopenia) and fat mass (Wijnhoven et al., 2005).

Last, it is relevant to note that independent of aging and age-related diseases, FOXO4-DRI may be of use against the progression, stemness, and migration of malignant cancer. Given that SASP factors influence these (Campisi, 2013), it will be particularly interesting to determine whether FOXO4-DRI affects those p53-wt cancer cells that have adopted a more migratory and stem-like state due to reprogramming by chronic SASP exposure. In any case, the here reported beneficial effects of FOXO4-DRI provide a wide range of possibilities for studying the potential of therapeutic removal of senescence against diseases for which few options are available.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mouse experiments
  - Cell culture
  - Kidney slice culture
- METHOD DETAILS
  - Antibodies and reagents
  - Lentivirus production and shRNAs
  - FOXO4 D-Retro-Inverso peptide development
  - Total RNA isolation and mRNA sequencing sample preparation

- Total RNA analysis pipeline (TRAP)
- Production and purification of recombinant proteins
- NMR spectroscopy
- Immunofluorescence and Structured Illumination Microscopy
- Quantitative real-time PCR
- Immunoblotting
- Cell viability assays
- Cell density assays
- Apoptosis assays
- Real-time cell density assay
- Real-time imaging of Caspase-3/7 activation
- Genotyping of mice
- Design of mouse experiments
- Assessment of running wheel activity
- Fur density analysis
- Infrared-measurements of abdominal temperature
- Immunohistochemistry
- Bioluminescence
- Plasma values as measure for tissue function
- Post mortem SA- $\beta$ -GAL assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

#### SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures, one table, and four movies and can be found with this article online at <http://dx.doi.org/10.1016/j.cell.2017.02.031>.

#### AUTHOR CONTRIBUTIONS

Conceptualization: P.L.J.d.K.; Methodology: M.P.B. and P.L.J.d.K.; Software: K.W.J.D., W.F.v.I.J., and J.P.; Validation: M.P.B., D.A.P., J.D.D.K., Y.R., H.v.W., D.A.F., and P.L.J.d.K.; Formal Analysis: M.P.B., D.A.P., J.D.D.K., K.W.J.D., B.J.R.M.B., S.S., H.v.W., D.A.F., I.v.d.P., W.A.v.C., T.M., and P.L.J.d.K.; Investigation: M.P.B., R.M.C.B., D.A.P., J.D.D.K., K.W.J.D., B.J.R.M.B., S.S., Y.R., H.v.W., D.A.F., I.v.d.P., T.M., and P.L.J.d.K.; Resources: W.F.v.I.J., A.B.H., J.P., R.W.F.d.B., and T.M.; Data Curation: K.W.J.D., T.M., and P.L.J.d.K.; Writing – Original Draft: P.L.J.d.K.; Writing – Review & Editing: M.P.B. and P.L.J.d.K.; Visualization: P.L.J.d.K. Supervision: J.E., T.M., J.C., and P.L.J.d.K.; Project Administration: T.M., J.H.J.H., J.C., and P.L.J.d.K.; Funding Acquisition: A.B.H., T.M., J.H.J.H., J.C., and P.L.J.d.K.

#### ACKNOWLEDGMENTS

We thank Felicity Chandler for assistance with IHC experiments, Anne Drabbe and David Brouwer for assistance with in vivo experiments, Yanto Ridwan for assistance with CT and IVIS imaging, Yvette van Loon for genotyping of the mice, Martin Viertler for initial NMR experiments, Boudewijn Burgering for fruitful discussions, and Petra de Keizer-Burger for critical reading of the manuscript. Judith Campisi is co-founder and shareholder of Unity Pharmaceuticals. Jan Hoeijmakers is co-founder of AgenD. Neither companies have been involved in this research, however.

This work was supported by grants from the NIH: R37-AG009909 (J.C.), the NIA: PPG AG-17242-02 (J.C. and J.H.J.H.), the Austrian Science Fund: FWF P28854 (T.M.), and DK-MCD W1226 (T.M.), the Royal Netherlands Academy of Arts and Sciences (J.H.J.H.), the Erasmus University Medical Center: EMC fellowship 2013 (P.L.J.d.K.), the Dutch Kidney Foundation: Grant 15OP11 (R.W.F.d.B. and P.L.J.d.K.), and the Dutch Cancer Society: fellowship Buit-4649 (P.L.J.d.K.) and project grant EMCR 2014-7141 (P.L.J.d.K.).

Received: August 11, 2016

Revised: December 29, 2016

Accepted: February 22, 2017

Published: March 23, 2017

#### REFERENCES

- Baker, D.J., Childs, B.G., Durik, M., Wijers, M.E., Sieben, C.J., Zhong, J., Saltness, R.A., Jeganathan, K.B., Verzosa, G.C., Pezeshki, A., et al. (2016). Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature* **530**, 184–189.
- Beydoun, T., Deloche, C., Perino, J., Kirwan, B.A., Combette, J.M., and Behar-Cohen, F. (2015). Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study. *J. Ocul. Pharmacol. Ther.* **37**, 93–99.
- Borsello, T., Clarke, P.G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D.F., Bogousslavsky, J., and Bonny, C. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nat. Med.* **9**, 1180–1186.
- Botter, S.M., Zar, M., van Osch, G.J., van Steeg, H., Dollé, M.E., Hoeijmakers, J.H., Weinans, H., and van Leeuwen, J.P. (2011). Analysis of osteoarthritis in a mouse model of the progeroid human DNA repair syndrome trichothiodystrophy. *Age (Dordr.)* **33**, 247–260.
- Brown, J.P., Wei, W., and Sedivy, J.M. (1997). Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. *Science* **277**, 831–834.
- Cahu, J., Bustany, S., and Sola, B. (2012). Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. *Cell Death Dis.* **3**, e446.
- Campisi, J. (2013). Aging, cellular senescence, and cancer. *Annu. Rev. Physiol.* **75**, 685–705.
- Chang, J., Wang, Y., Shao, L., Laberge, R.M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N.E., Ding, S., Feng, W., et al. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat. Med.* **22**, 78–83.
- Coppé, J.P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* **6**, 2853–2868.
- Damodar, G., Smitha, T., Gopinath, S., Vijayakumar, S., and Rao, Y. (2014). An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. *Ann. Med. Health Sci. Res.* **4**, 74–79.
- de Boer, J., Andressoo, J.O., de Wit, J., Huijman, J., Beems, R.B., van Steeg, H., Weeda, G., van der Horst, G.T., van Leeuwen, W., Themmen, A.P., et al. (2002). Premature aging in mice deficient in DNA repair and transcription. *Science* **296**, 1276–1279.
- de Boer, J., de Wit, J., van Steeg, H., Berg, R.J., Morreau, H., Visser, P., Lehmann, A.R., Duran, M., Hoeijmakers, J.H., and Weeda, G. (1998). A mouse model for the basal transcription/DNA repair syndrome trichothiodystrophy. *Mol. Cell* **1**, 981–990.
- de Keizer, P.L. (2017). The Fountain of Youth by Targeting Senescent Cells? *Trends Mol. Med.* **23**, 6–17.
- de Keizer, P.L., Burgering, B.M., and Dansen, T.B. (2011). Forkhead box o as a sensor, mediator, and regulator of redox signaling. *Antioxid Redox Signal* **14**, 1093–1106.
- de Keizer, P.L., Packer, L.M., Szypowska, A.A., Riedl-Polderman, P.E., van den Broek, N.J., de Bruin, A., Dansen, T.B., Marais, R., Brenkman, A.B., and Burgering, B.M. (2010). Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. *Cancer Res.* **70**, 8526–8536.
- Degenhardt, K., Sundararajan, R., Lindsten, T., Thompson, C., and White, E. (2002). Bax and Bak independently promote cytochrome C release from mitochondria. *J. Biol. Chem.* **277**, 14127–14134.

- Deloche, C., Lopez-Lazaro, L., Mouz, S., Perino, J., Abadie, C., and Combette, J.M. (2014). XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. *Pharmacol. Res. Perspect.* *2*, e00020.
- Demaria, M., Ohtani, N., Youssef, S.A., Rodier, F., Toussaint, W., Mitchell, J.R., Laberge, R.M., Vijg, J., Van Steeg, H., Dollé, M.E., et al. (2014). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. *Dev. Cell* *31*, 722–733.
- Di Leonardo, A., Linke, S.P., Clarkin, K., and Wahl, G.M. (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. *Genes Dev.* *8*, 2540–2551.
- Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc. Natl. Acad. Sci. USA* *92*, 9363–9367.
- Eijkelenboom, A., and Burgering, B.M. (2013). FOXOs: signalling integrators for homeostasis maintenance. *Nat. Rev. Mol. Cell Biol.* *14*, 83–97.
- Ewald, J.A., Desotelle, J.A., Wilding, G., and Jarrard, D.F. (2010). Therapy-induced senescence in cancer. *J. Natl. Cancer Inst.* *102*, 1536–1546.
- Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D.D., Guralnik, J.M., and Longo, D.L. (2005). The origins of age-related proinflammatory state. *Blood* *105*, 2294–2299.
- Freund, A., Laberge, R.M., Demaria, M., and Campisi, J. (2012). Lamin B1 loss is a senescence-associated biomarker. *Mol. Biol. Cell* *23*, 2066–2075.
- Freund, A., Patil, C.K., and Campisi, J. (2011). p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. *EMBO J.* *30*, 1536–1548.
- Gowda, S., Desai, P.B., Kulkarni, S.S., Hull, V.V., Math, A.A., and Vernekar, S.N. (2010). Markers of renal function tests. *N. Am. J. Med. Sci.* *2*, 170–173.
- Guichard, G., Benkirane, N., Zeder-Lutz, G., van Regenmortel, M.H., Briand, J.P., and Muller, S. (1994). Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. *Proc. Natl. Acad. Sci. USA* *91*, 9765–9769.
- Henderson, T.O., Ness, K.K., and Cohen, H.J. (2014). Accelerated aging among cancer survivors: from pediatrics to geriatrics. *Am. Soc. Clin. Oncol. Educ. Book 2014*, e423–e430.
- Herce, H.D., and Garcia, A.E. (2007). Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. *Proc. Natl. Acad. Sci. USA* *104*, 20805–20810.
- Hoeijmakers, J.H. (2009). DNA damage, aging, and cancer. *N. Engl. J. Med.* *361*, 1475–1485.
- Hosaka, T., Biggs, W.H., 3rd, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., and Arden, K.C. (2004). Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. *Proc. Natl. Acad. Sci. USA* *101*, 2975–2980.
- Krishnamurthy, J., Torrice, C., Ramsey, M.R., Kovalev, G.I., Al-Regaiey, K., Su, L., and Sharpless, N.E. (2004). Ink4a/Arf expression is a biomarker of aging. *J. Clin. Invest.* *114*, 1299–1307.
- Kruiswijk, F., Hasenfuss, S.C., Sivapatham, R., Baar, M.P., Putavet, D., Naipal, K.A., van den Broek, N.J., Kruit, W., van der Spek, P.J., van Gent, D.C., et al. (2016). Targeted inhibition of metastatic melanoma through interference with Pin1-FOXO signaling. *Oncogene* *35*, 2166–2177.
- Kruiswijk, F., Labuschagne, C.F., and Vousden, K.H. (2015). p53 in survival, death and metabolic health: a lifeguard with a licence to kill. *Nat. Rev. Mol. Cell Biol.* *16*, 393–405.
- López-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. *Cell* *153*, 1194–1217.
- Lyman, J.L. (1986). Blood urea nitrogen and creatinine. *Emerg. Med. Clin. North Am.* *4*, 223–233.
- Martins, R., Lithgow, G.J., and Link, W. (2016). Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. *Aging Cell* *15*, 196–207.
- Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U.M. (2003). p53 has a direct apoptogenic role at the mitochondria. *Mol. Cell* *11*, 577–590.
- Muñoz-Espín, D., Cañamero, M., Maraver, A., Gómez-López, G., Contreras, J., Murillo-Cuesta, S., Rodríguez-Baeza, A., Varela-Nieto, I., Ruberte, J., Collado, M., and Serrano, M. (2013). Programmed cell senescence during mammalian embryonic development. *Cell* *155*, 1104–1118.
- Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W.H., 3rd, Arden, K.C., and Accilli, D. (2003). The forkhead transcription factor Foxo1 regulates adipocyte differentiation. *Dev. Cell* *4*, 119–129.
- Orjalo, A.V., Bhaumik, D., Gengler, B.K., Scott, G.K., and Campisi, J. (2009). Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. *Proc. Natl. Acad. Sci. USA* *106*, 17031–17036.
- Paik, J.H., Kollipara, R., Chu, G., Ji, H., Xiao, Y., Ding, Z., Miao, L., Tothova, Z., Horner, J.W., Carrasco, D.R., et al. (2007). FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. *Cell* *128*, 309–323.
- Renault, V.M., Rafalski, V.A., Morgan, A.A., Salihi, D.A., Brett, J.O., Webb, A.E., Villeda, S.A., Thekkat, P.U., Guillerey, C., Denko, N.C., et al. (2009). FoxO3 regulates neural stem cell homeostasis. *Cell Stem Cell* *5*, 527–539.
- Rodier, F., Coppé, J.P., Patil, C.K., Hoeijmakers, W.A., Muñoz, D.P., Raza, S.R., Freund, A., Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. *Nat. Cell Biol.* *11*, 973–979.
- Rodier, F., Muñoz, D.P., Teachenor, R., Chu, V., Le, O., Bhaumik, D., Coppé, J.P., Campeau, E., Beauséjour, C.M., Kim, S.H., et al. (2011). DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. *J. Cell Sci.* *124*, 68–81.
- Roninson, I.B. (2003). Tumor cell senescence in cancer treatment. *Cancer Res.* *63*, 2705–2715.
- Schoenwaelder, S.M., Jarman, K.E., Gardiner, E.E., Hua, M., Qiao, J., White, M.J., Josefsson, E.C., Alwis, I., Ono, A., Willcox, A., et al. (2011). Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. *Blood* *118*, 1663–1674.
- Suckfuell, M., Lisowska, G., Domka, W., Kabacinska, A., Morawski, K., Bodlaj, R., Klimak, P., Kostrica, R., and Meyer, T. (2014). Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study. *Otol. Neurotol.* *35*, 1317–1326.
- Tait, S.W., and Green, D.R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* *11*, 621–632.
- Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. *Science* *347*, 1260419.
- Vaupel, J.W. (2010). Biodemography of human ageing. *Nature* *464*, 536–542.
- Wang, E. (1995). Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. *Cancer Res.* *55*, 2284–2292.
- Wang, F., Marshall, C.B., Yamamoto, K., Li, G.Y., Plevin, M.J., You, H., Mak, T.W., and Ikura, M. (2008). Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. *J. Mol. Biol.* *384*, 590–603.
- Warso, M.A., Richards, J.M., Mehta, D., Christov, K., Schaeffer, C., Rae-Bressler, L., Yamada, T., Majumdar, D., Kennedy, S.A., Beattie, C.W., and Das Gupta, T.K. (2013). A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. *Br. J. Cancer* *108*, 1061–1070.
- Wijnhoven, S.W., Beems, R.B., Roodbergen, M., van den Berg, J., Lohman, P.H., Diderich, K., van der Horst, G.T., Vijg, J., Hoeijmakers, J.H., and van Steeg, H. (2005). Accelerated aging pathology in ad libitum fed Xpd(TTD) mice is accompanied by features suggestive of caloric restriction. *DNA Repair (Amst.)* *4*, 1314–1324.

- Wilhelm, M., Schlegl, J., Hahne, H., Moghaddas Gholami, A., Lieberenz, M., Savitski, M.M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014). Mass-spectrometry-based draft of the human proteome. *Nature* *509*, 582–587.
- Xu, M., Tchkonina, T., Ding, H., Ogrodnik, M., Lubbers, E.R., Pirtskhalava, T., White, T.A., Johnson, K.O., Stout, M.B., Mezera, V., et al. (2015). JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. *Proc. Natl. Acad. Sci. USA* *112*, E6301–E6310.
- Yosef, R., Pilpel, N., Tokarsky-Amiel, R., Biran, A., Ovadya, Y., Cohen, S., Vadai, E., Dassa, L., Shahar, E., Condiotti, R., et al. (2016). Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. *Nat. Commun.* *7*, 11190.
- Zhou, W., Cao, Q., Peng, Y., Zhang, Q.J., Castrillon, D.H., DePinho, R.A., and Liu, Z.P. (2009). FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. *Gastroenterology* *137*, 1403–1414.
- Zhu, Y., Tchkonina, T., Pirtskhalava, T., Gower, A.C., Ding, H., Giorgadze, N., Palmer, A.K., Ikeno, Y., Hubbard, G.B., Lenburg, M., et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* *14*, 644–658.



## STAR★METHODS

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse monoclonal anti-53BP1	Millipore	Cat#05-726; RRID: AB_309939
Mouse monoclonal anti-BCL2	Abcam	Cat#Ab7972; RRID: AB_305670
Rabbit monoclonal anti-BIM	Cell signaling	Cat#C3C5; RRID:AB_1030947
Rabbit polyclonal anti-Cleaved Caspase-3	Cell signaling	Cat#9661; RRID: AB_2341188
Mouse monoclonal anti-Cytochrome C	BD Pharmigen	Cat#556432; RRID: AB_396416
Rabbit monoclonal anti-FOXO1	Cell signaling	Cat#2880; RRID: AB_2106495
Rabbit polyclonal anti-FOXO1	Millipore	Cat#07-702; RRID: AB_441949
Rabbit polyclonal anti-FOXO4	Cell signaling	Cat#9472; RRID: AB_10831833
Rabbit polyclonal anti-FOXO4	Sigma	Cat#HPA040232
Rabbit polyclonal anti-Histone H3	Abcam	Cat#ab1791-100; RRID: AB_302613
Mouse monoclonal anti-HIV1 TAT	Abcam	Cat#ab63957; RRID: AB_1139536
Mouse monoclonal anti-IL1 $\alpha$ clone 4414	R&D systems	Cat#MAB200; RRID: AB_2295862
Rabbit polyclonal anti-IL6	Abcam	Cat#ab6672; RRID: AB_2127460
Goat polyclonal anti-IL6	R&D systems	Cat#AF206NA; RRID: AB_354392
Rabbit polyclonal anti-LMNB1	Abcam	Cat#ab16048; RRID: AB_10107828
Mouse monoclonal anti-p16Ink4a clone JC8	Santa Cruz	Cat#sc56330; RRID: AB_785018
Mouse monoclonal anti-p21Cip1	BD Transduction Laboratories	Cat#610234; RRID: AB_397629
Rabbit polyclonal anti-p53	Novacastra	Cat#NCL-p53-CM55
Mouse monoclonal anti-phospho-Ser15 p53	Cell signaling	Cat#9286; RRID: AB_10828826
Goat polyclonal anti-PML N19	Santa Cruz	Cat#sc9862; RRID: AB_2166847
Rabbit polyclonal anti-PUMA	Cell signaling	Cat#4976; RRID: AB_10693473
Mouse monoclonal anti-Tubulin clone B512	Sigma	Cat#T5168; RRID: AB_477579
Donkey anti-Goat 594	Thermo Fischer	Cat#A-11058; RRID: AB_2534105
Donkey anti-Goat 647	Thermo Fisher	Cat#A-21447; RRID: AB_141844
Donkey anti-Mouse 488	Thermo Fischer	Cat#A-21202; RRID: AB_141607
Donkey anti-Mouse 594	Thermo Fischer	Cat#A-21203; RRID: AB_141633
Donkey anti-Rabbit 488	Thermo Fischer	Cat#A-21206; RRID: AB_2535792
Donkey anti-Rabbit 594	Thermo Fischer	Cat#A-21207; RRID: AB_141637
Donkey anti-Mouse HRP	Dako	Cat#P0161
Donkey anti-Rabbit HRP	Dako	Cat#P0448
<b>Bacterial and Virus Strains</b>		
E.coli BL21 (DE3)	Agilent Technologies	CAT#: 200131; Lot#: 0006276950
<b>Chemicals, Peptides, and Recombinant Proteins</b>		
Benzonase Nuclease	Sigma Aldrich	CAS#: E1014; Lot#: SLBM6125V
Doxorubicin	Santa Cruz	Cat#sc-200923A
FOXO4 D-Retro-Inverso peptide	This paper, manufactured by Pepscan	N/A
H-ltlrkepaseiaqsileaysqngwanrrsggkrpprrrrqrkrkrg-OH		
NucView488 Caspase-3	Essen Bioscience	Cat#4440
QVD-OPH	BD biosciences	Cat#03OPH10905
Rotenone	Sigma-Aldrich	Cat#R8875
VECTASHIELD Antifade Mounting Medium with DAPI	Vector Laboratories	Cat# H1200
Xenolight RediJect Coelentarazine	Caliper	Cat#770505

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
ZVAD-FMK	R&D systems	Cat#FMK001
<b>Critical Commercial Assays</b>		
AST Activity Assay Kit	Sigma	Cat#MAK055
AqueousOne Solution Cell Proliferation Assay	Promega	Cat#G3582
Creatinine assay kit	Sigma	Cat#MAK080
In Situ Cell Death Detection Kit	Roche	Cat#11684795910
miRNeasy mini kit	QIAGEN	Cat#217004
QuantiChrom Urea Assay Kit	Gentaur	Cat#DIUR-500
TruSeq mRNA sample preparation kit	Illumina	Cat#RS-122-2101
<b>Deposited Data</b>		
RNA sequencing data	This study	GSE94395
<b>Experimental Models: Cell Lines</b>		
BJ	ATCC	Cat#CRL-2522
BMK cells, wt and <i>Bax/Bak</i> <sup>-/-</sup>	Gift from Dr. Eileen White.(Degenhardt et al., 2002)	N/A
HEK293LTV	ATCC	Cat#CRL-1573
IMR90	ATCC	Cat#CCL-186
NIH 3T3	ATCC	Cat#CRL-1658
WI-38	ATCC	Cat#CCL-75
<b>Experimental Models: Organisms/Strains</b>		
Mouse: C57BL/6J	(de Boer et al., 1998)	N/A
Mouse: C57BL/6J p16::3MR	(Demaria et al., 2014)	N/A
Mouse: C57BL/6J <i>Xpd</i> <sup>TTD/TTD</sup>	(de Boer et al., 1998)	N/A
<b>Oligonucleotides</b>		
Primers for QPCR and genotyping, see Table S1	This paper	N/A
shFOXO4-1 CCAGCTTCAGTCAGCAGTTAT	GPP	TRCN0000039720
shFOXO4-2 CGTCCACGAAGCAGTTCAAAT	GPP	TRCN0000039721
shFOXO4(mouse) GATCTGGATCTTGATATGTAT	GPP	TRCN0000071560
shp53-1 CGGCGCACAGAGGAAGAGAAT	GPP	TRCN0000003753
shp53-2 CGGCGCACAGAGGAAGAGAAT	GPP	TRCN0000003754
<b>Recombinant DNA</b>		
pETM-11	EMBL Heidelberg	N/A
pUC-FOXO4 <sup>B6-206</sup>	GenScript	N/A
pUC-p53 <sup>1-312</sup>	GenScript	N/A
<b>Software and Algorithms</b>		
CcpNmr 2.4.2	CCPN	<a href="http://www.ccpn.ac.uk/v2-software/downloads/stable">http://www.ccpn.ac.uk/v2-software/downloads/stable</a>
Ingenuity Pathway Analysis Software, version build 242990	QIAGEN	<a href="https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/">https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/</a>
TopSpinTM 3.1	Bruker	<a href="https://www.bruker.com/products/mr/nmr/nmr-software/software.html">https://www.bruker.com/products/mr/nmr/nmr-software/software.html</a>
TRAP	ErasmusMC	<a href="http://rna-ome.erasmusmc.nl/">http://rna-ome.erasmusmc.nl/</a>
<b>Other</b>		
Ammonium chloride (15N, 99%)	Cambridge Isotope Laboratories, Inc	CAS#: 12125-02-9; Lot#: 13K-451
D-Glucose (U- <sup>13</sup> C <sub>6</sub> , 99%)	Cambridge Isotope Laboratories, Inc	CAS#: 110187-42-3; Lot#: PR-26833
Deuterium oxide (99.9 atom %D)	Sigma Aldrich	CAS#: 7789-20-0; Lot#: STBF0098V

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter L.J. de Keizer ([p.dekeizer@erasmusmc.nl](mailto:p.dekeizer@erasmusmc.nl)). The following materials:  $Xpd^{TTD/TTD}$  mice; p16::3MR mice and the peptide FOXO4-DRI are subject to patent applications and may be shared with research organizations for research and educational purposes only under an MTA to be discussed in good faith with the recipient; such MTA may restrict recipient to make any modifications to these materials.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Mouse experiments

This study was performed in strict accordance with all applicable federal and institutional policies. The protocol was approved by the Dutch Animal Ethics Committee. All the mice used in this study were of a C57BL/6J background; either wild-type,  $Xpd^{TTD/TTD}$  mutated, expressing p16::3MR, or a combination thereof. The individual strains were backcrossed at least 10 times prior to this study. For the combination  $Xpd^{TTD/TTD}$  x p16::3MR the F1 generation was used. The mice were used at the ages indicated in the figures, for Doxorubicin-experiments at 10-40wks of age, for  $Xpd^{TTD/TTD}$  versus wt experiments at 26-60 wks of age and for naturally aged mice at 115-130wks of age. All mice were kept in group housing until the start of the experiment after which they were placed in individual cages containing free access to a running wheel. Both sexes were used throughout the study. Where feasible, littermates of the same sex were used. These were randomly assigned to experimental groups.

### Cell culture

The following cell lines were used in this study: IMR90 and WI-38 human fetal lung fibroblasts (female), BJ human foreskin fibroblasts (male), NIH 3T3 mouse fibroblasts, wt and  $bax/bak^{-/-}$  littermate Baby Mouse Kidney (BMK) cells, Human Embryonic Kidney (HEK) 293LTV. All cells were obtained from ATCC, except for wt and  $bax/bak^{-/-}$  BMK cells which were a kind gift of Dr. Eileen White and have previously been described (Degenhardt et al., 2002). All cells were maintained in high glucose Dulbecco's Modified Eagle's Medium (Lonza), supplemented with 10% Fetal Calf Serum, penicillin/streptomycin and 0.05% glutamine. IMR90, BJ, WI-38 cells were kept at 5% CO<sub>2</sub>, 3% O<sub>2</sub> and used between 28-45 population doublings. The BMK cells were kept at 5% CO<sub>2</sub>, 3% O<sub>2</sub>. The NIH 3T3 and HEK293LTV cells were maintained at 5% CO<sub>2</sub>, ambient O<sub>2</sub>. All cell lines were regularly tested for mycoplasma contamination using MycoAlert Mycoplasma Detection Kit (Lonza) and by assessment of (lack of) DAPI-positive microvesicles under fluorescence microscope. For IR-induced senescence, cells were exposed to 10Gy X- or Gamma rays, and analyzed 10 days later or otherwise indicated; control (proliferating) cells were mock irradiated, meaning they were taken out of the incubator and carried to the irradiator where they were placed outside for the same period of time as the irradiated cells. Senescence was confirmed by SA-β-GAL assay (Dimri et al., 1995) and/or changes in morphology. For Doxorubicin-induced senescence, the cells were treated twice with 0.1 μM Doxorubicin (Sigma) with a 2d interval and analyzed 7d later, or as otherwise indicated.

### Kidney slice culture

For tissue slice experiments, mice were used for which approval was obtained from the Committee on the Ethics of Animal Experiments of the Erasmus MC, where possible as a left-over from other experiments. Freshly isolated kidneys were sectioned in 200 μM thick slices using a Vibratome (Leica, Eindhoven, the Netherlands). The sections were cultured in Dulbecco's modified eagle medium with 10% FCS at 37 °C, 5% CO<sub>2</sub> on a shaker (60 rpm). Following incubation with shRNA-containing lentiviral particles, or FOXO4-DRI, as indicated, the slices were fixed for 30min in formalin and stored at -80. Subsequently, they were subsectioned to 10 μM slices using a Cryostat, placed on a charged microscopy slide and processed for TUNEL positivity.

## METHOD DETAILS

### Antibodies and reagents

Antibodies against the following proteins were used (See also [Key Resource Table](#)): Cell Signaling: FOXO1 (2880), FOXO4 (9472), Phospho-Ser15 p53 (9286), PUMA (4976), BIM (C3C5), Cleaved Caspase-3 (9661), Sigma: FOXO4 (HPA040232), Tubulin (clone B512; no: T5168), Abcam: BCL2 (Ab7972), IL6 (ab6672), Histone H3 (Ab1791-100), BD Transduction Laboratories: p21<sup>Cip1</sup> (610234), BD Pharmingen: Cytochrome C (556432), R&D systems: IL1α clone 4414, MAB200, human IL6 (AF206NA), Upstate: 53BP1 (05-726), Millipore: FOXO1 (07-702), Santa Cruz: p16<sup>Ink4a</sup> (JC8; sc56330), PML (N19; sc9862), LMNB1 (M-20; sc-6217), Novacastra: mouse p53 (NCL-p53-CM55).

The following reagents were used: QVD-OPH (BD biosciences), ZVAD-FMK (SelleckChem), Rotenone (Sigma-Aldrich, St. Louis, MO, USA), Doxorubicin (Santa Cruz).

### Lentivirus production and shRNAs

Lentiviruses were produced in an MLII-certified lab area, using the 3<sup>rd</sup> generation production system. In brief, HEK293LTV cells were transfected (Lipofectamine2000) with the packaging/envelope plasmids pRSV-Rev, pMDLg/pRRE and pMD2.G, in combination with a lentiviral transfer plasmid of choice. The next day, the media was refreshed. After 48h, the media was collected for transduction and

stored at 4°C until needed. The following shRNA constructs were used (See also [Key Resources Table](#)): shGFP, shFOXO4-1: TRCN0000039720, Mature sequence: CCAGCTTCAGTCAGCAGTTAT, shFOXO4-2: TRCN0000039721, Mature sequence: CGTCCACGAAGCAGTTCAAT, shFOXO4(mouse): TRCN0000071560, Mature sequence: GATCTGGATCTTGATATGTAT, shp53-1: TRCN000003753, Mature sequence: CGGCGCACAGAGGAAGAGAAT and shp53-2: TRCN000003754, Mature sequence: TCAGACCTATGGAACTACTT. For transient expression of FOXO1, we transfected cells with pBabe-Puro-FOXO1 ([de Keizer et al., 2010](#)). For stable transduction of HRAS<sup>G12V</sup>, we used pLENTI-Puro (670-1)-HRAS<sup>G12V</sup> ([Freund et al., 2012](#)). The day after transduction, the cells were refreshed and 24h later placed on selection in media containing 0.5 µg/ml puromycin. Three days later, the media was refreshed with media containing 1 µg/ml puromycin in which they were kept throughout the assay. After 7d of selection, the cells were used in their respective assays. The shRNA-transduced cells were subsequently exposed to senescence-inducing IR and processed for Cell viability after 6d. For assays on IMR90 cells that were already senescent, treatment occurred as indicated ([Figure S1C](#)) and the cells were subsequently processed for cell viability or cell density.

### FOXO4 D-Retro-Inverso peptide development

FOXO4-DRI consists of the following amino acid sequence in D-Isoform:

H-ltrkepaseiaqsileaysqngwanrrsggkrpprrrrqrrkrqg-OH. MW: 5358.2 It was manufactured by Pepscan (Lelystad, the Netherlands) at > 95% purity and stored at -20°C in 1mg powder aliquots until used to avoid freeze-thawing artifacts. For in vitro experiments FOXO4-DRI was dissolved in PBS to generate a 2mM stock. For in vivo use, FOXO4-DRI was dissolved in PBS to generate a 5mg/ml stock solution, which was kept on ice until injection. Before injection the solution was brought to room temperature.

### Total RNA isolation and mRNA sequencing sample preparation

The total RNA isolation and sequencing library preparation from IR-induced senescent and proliferating IMR90 cells was performed as follows: total RNA was isolated using Qiazol Lysis Reagent (QIAGEN) and purified with the miRNeasy kit (QIAGEN). The integrity (scores > 9.0) of the RNA was determined on the Agilent 2100 Bioanalyzer (Agilent). Total RNA enrichment for sequencing poly(A) RNAs was performed with the TruSeq mRNA sample preparation kit (Illumina). 1 µg of total RNA for each sample was used for poly(A) RNA selection using magnetic beads coated with poly-dT, followed by thermal fragmentation. The fragmented poly(A) RNA enriched samples were subjected to cDNA synthesis using Illumina TruSeq preparation kit. cDNA was synthesized by reverse transcriptase (Super-Script II) using poly-dT and random hexamer primers. The cDNA fragments were then blunt-ended through an end-repair reaction, followed by dA-tailing. Subsequently, specific double-stranded bar-coded adapters were ligated and library amplification for 15 cycles was performed. The pooled cDNA library consisted of equal concentration bar-coded samples. The pooled library was sequenced in one lane, 36 bp single read on the HiSeq2500 (Illumina). The analysis of the sequencing dataset was performed by Total RNA analysis pipeline (TRAP).

### Total RNA analysis pipeline (TRAP)

Reads were aligned to the human hg19 reference genome using the NARWHAL automation software. Exonic reads were summed per transcript. A specific transcript was considered expressed, when a minimum number of reads, i.e., 5 reads per million, could be aligned to a transcript. Pathway analysis was performed with Ingenuity Pathway Analysis Software (IPA; Version build 242990).

### Production and purification of recombinant proteins

The constructs corresponding to human FOXO4 (residues 86 – 206) and human p53 (residues 1 – 312), were purchased from GenScript in a pUC cloning vector. The DNA sequence was codon optimized for protein production in bacterial cells and flanked by NcoI and BamHI restriction sites. The coding region was cloned into a modified pETM-11 bacterial expression vector (EMBL Heidelberg) which was derived from a pET-24d(+) vector (Novagen) by insertion of a tobacco etch virus (TEV) protease cleavage site following a N-terminal hexa-histidine and protein A tag. The genes were amplified by PCR using T4 primers (New England Biolabs). The resulting PCR products and pETM-11 were double digested with NcoI and BamHI enzymes (New England Biolabs) before ligation. The construct was verified by sequencing.

The human p53<sup>1-312</sup>, and FOXO4<sup>86-206</sup> DNA sequences were codon optimized for protein production in bacterial cells and flanked by NcoI and BamHI restriction sites. The coding region was cloned into a modified pETM-11 bacterial expression vector which was derived from a pET-24d(+) vector (Novagen) by insertion of a tobacco etch virus (TEV) protease cleavage site following a N-terminal hexa-histidine and protein A tag.

Unlabeled and uniformly (<sup>15</sup>N) labeled protein was produced in freshly transformed *E. coli* BL-21 (DE3) cells. A single colony was inoculated in Luria-Bertani medium (20 ml) with kanamycin (25 mg l<sup>-1</sup>) and cultured at 37°C overnight. From this, an aliquot (1 ml) was added to either 1 l unlabeled Luria-Bertani medium or 1 l <sup>15</sup>N labeled M9 minimal medium (100 mM KH<sub>2</sub>PO<sub>4</sub>, 50 mM K<sub>2</sub>HPO<sub>4</sub>, 60 mM Na<sub>2</sub>HPO<sub>4</sub>, 14 mM K<sub>2</sub>SO<sub>4</sub>, 5 mM MgCl<sub>2</sub>, pH 7.2 adjusted with HCl and NaOH with 0.1 dilution of trace element solution (41 mM CaCl<sub>2</sub>, 22 mM FeSO<sub>4</sub>, 6 mM MnCl<sub>2</sub>, 3 mM CoCl<sub>2</sub>, 1 mM ZnSO<sub>4</sub>, 0.1 mM CuCl<sub>2</sub>, 0.2 mM (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>, 17 mM EDTA) with kanamycin (25 mg l<sup>-1</sup>) in which <sup>15</sup>N-NH<sub>4</sub>Cl (2 g l<sup>-1</sup>) was the only source of nitrogen for NMR isotope labeling purposes, respectively (Cambridge Isotope Laboratories, Inc). The culture was incubated at 37°C and shaken at 200 rpm until the OD<sub>600</sub> reached 0.8. Protein expression was induced with 1 mM β-D-1-thiogalactopyranoside (IPTG) at 18°C. The cells were pelleted after 20 hr by centrifugation using a Fiberlite F9-6x1000 rotor in a Sorvall LYNX 6000 Superspeed centrifuge at 2,000 g for 20 min, re-suspended in 40 mL lysis buffer containing

50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM imidazole, 20% glycerol, 2 mM TCEP, 250 units of Benzonase® Nuclease and bacterial Protease Inhibitor Cocktail (Amresco; AEBSF, E-64, Bestatin, EDTA and Pepstatin) and were subsequently lysed by sonication. Lysates were cleared by centrifugation for 45 min at 4°C (12 000 rpm; Sorvall Lynx 6 000) and filtration (0.45 µm cellulose acetate syringe filters). Proteins were purified using Ni-NTA resins for immobilized metal affinity chromatography. Lysate was applied on the column and contaminants were removed using Wash buffer 1 (50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM imidazole and 2 mM TCEP) and Wash buffer 2 (50 mM Tris, pH 7.5, 1 M NaCl, 20 mM imidazole and 2 mM TCEP). Protein was eluted (50 mM Tris, pH 7.5, 1 M NaCl, 500 mM imidazole and 2 mM TCEP) and the His6-Protein A tag was cleaved overnight at 4°C using 2 (w/w) % of 1 mg/ml recombinant His-tagged TEV protease. The protein solution was buffer exchanged to Wash buffer 1 using HiPrep 26/10 Desalting column on an ÄKTA Pure system (GE Healthcare) at room temperature. Cleaved protein was repurified from the cleaved fusion tag and TEV protease by loading on a Ni-NTA resin column and 5 mL of the flow through was applied to a size-exclusion column (HiLoad Sepharose 16/600 75 µg, GE Healthcare) on an ÄKTA Pure system (GE Healthcare) at RT. The corresponding running buffer was composed of 50 mM sodium phosphate, pH 6.5, 150 mM NaCl and 1 mM DTT.

### NMR spectroscopy

Samples for NMR measurements contained 300 µM <sup>15</sup>N labeled FOXO4<sup>86-206</sup> protein in 50 mM sodium phosphate, pH 6.5, 150 mM NaCl and 1 mM DTT with 10% 2H<sub>2</sub>O added for the lock signal. For NMR titrations, 0.2, 0.4, 0.8 and 1.0 stoichiometric equivalents of p53<sup>1-312</sup> (corresponding to 60, 120, 240 or 300 µM, respectively) and 1.0 and 2.0 stoichiometric equivalents of FOXO4-DRI (corresponding to 300 or 600 µM, respectively) were added. <sup>1</sup>H-<sup>15</sup>N HSQC NMR spectra were recorded at 298 K on a 700 MHz Bruker NMR spectrometer. All spectra were recorded with an interscan delay of 1.0 s, spectral widths of 15.9/30 ppm, centered at 4.7/118.0 ppm in <sup>1</sup>H/<sup>15</sup>N, with 1,024 and 256 points, respectively, and 16 scans per increment. NMR chemical shift assignments of FOXO4<sup>86-206</sup> were obtained from HNCACB and HNCA spectra using 500 µM of uniformly <sup>15</sup>N, <sup>13</sup>C labeled protein in the aforementioned buffer at 298K on a 900 MHz Bruker Avance III NMR spectrometer equipped with a TCI cryoprobe.

### Immunofluorescence and Structured Illumination Microscopy

Cells (typically 20,000) were grown on coverslips and after the indicated treatment fixed with formalin. Subsequently, cells were washed in Tris Buffered Saline (TBS) and permeabilized for 2-5 min in 2% Triton X-100 in TBS, depending on the antibody. Especially, the FOXO4 antibody (Cell Signaling) seemed to work better with shorter permeabilization times. To reduce background staining, the cells were quenched for 10min with 50mM glycine in TBS and blocked for 30min with 5% Normal Horse Serum (NHS) or Normal Goat Serum (NGS) in 0,2% gelatin-TBS solution, depending on the isotype of the secondary antibody. Subsequently, 30µl droplets containing primary antibody dilutions were placed on parafilm in a dark moisture chamber. The coverslips were placed facing the droplets and incubated overnight at 4°C. The next day, the coverslips were lifted by adding a small volume (~200µl) of TBS-Gelatine under the coverslip and transferred back to the 24-well plate. After washing 3x 20min with 1ml 0,2% gelatin-TBS secondary antibody incubation occurred as described for the primary antibody and the coverslips were incubated for one hour at room temperature. Following 3x 10min washes with 1ml 0,2% TBS-Gelatin and 1 wash with regular TBS the slides were mounted using soft set mounting medium with DAPI (Vectashield) and sealed with nail polish. Structured Illumination Microscopy was performed using a Zeiss Elyra PS1 microscope using a 63x 1.4 (n.a.) plan apo chromate oil immersion lens and 5 phases and 5 rotations of the illumination pattern. Intensity plots of individual pixels taken from a straight line in indicated immunofluorescence images were generated by twin slicer analysis using Huygens Professional 4.0 software (SVI, the Netherlands). Images were cropped and processed in Adobe Photoshop. When comparisons were made between images of the same experiment, all levels were adjusted equally and the ratio between the levels was not altered.

### Quantitative real-time PCR

mRNA was extracted using the Cells-to-Ct kit (Ambion). QPCR was performed using the Universal Probe Library system (Roche) with the following primer/probe combinations (5'-3'), also listed in [Table S1](#):

FOXO1 (NM\_002015.3): Fwd: tggtttagaaaccaagttcc, Rev: ttggcaccaagttcagttaca. UPL75  
 FOXO3 (NM\_001455.3): Fwd: cagtagggcctgtgattcc, Rev: cagcagaccaactgttcac. UPL73  
 FOXO4 (NM\_005938.2): Fwd: acgagtggatggtccgtact, Rev: gtggcggatcgagttcttc. UPL18  
 P21Cip1 (CDKN1A; NM\_000389.3): Fwd: cgaagtcagttcctgtggag, Rev: catgggtctgacggacat. UPL82  
 ETS2 (NM\_005239.4): Fwd: cagcgtcacctactgctctg, Rev: agtcgtggtctttgggagtc. UPL27  
 Tubulin (NM\_006009.2): Fwd: cttcgtctccgccatcag, Rev: ttgccaatctggacacca. UPL58

### Immunoblotting

The dishes were washed 2x with ice-cold PBS, lysed in 1x Laemli sample buffer, and subjected to standard SDS-PAGE using separate 4%–12% Bis-Tris gels, after which the proteins were overnight transferred at 4°C to polyvinylidene fluoride membranes. The membranes were blocked using 2% BSA in Tris-buffered saline, 0.05% TWEEN (TBS-T) for 60min and incubated overnight at 4°C with the indicated primary antibodies. Following at least two 20min washing steps with TBS-T, the membranes were incubated



with secondary antibodies for 60min. Following at least two 15min washing steps the membranes were developed with Enhanced Chemical Luminescence (Perkin Elmer). Images were cropped and equally processed in Adobe Photoshop.

### Cell viability assays

The cells were plated in triplicate in 96-well plates (typically 7000 senescent and 2000 non-senescent cells). Unless otherwise indicated, cell viability was assessed 6d after plating, using the AQueousOne Solution Cell Proliferation Assay (Promega). 10  $\mu$ l of Cell-Titer AQueousOne Solution in 100 $\mu$ l fresh culture medium was added to the wells before a 1-3 hr incubation at 37°C. Absorbance was measured at 490nm at a GloMax 96 well plate reader (Promega). A Mock-treated and a Puromycin (10  $\mu$ g/ml)-treated condition were used to set the maximal and minimal viability values, respectively, to which the experimental values were normalized.

### Cell density assays

Stably transduced and Puromycin-selected IMR90 cells were plated in 24-well plates in triplicate. After 3d, cells were fixed in methanol and stained with 0.5% crystal violet in 25% methanol. The plates were dried, and cell density was quantified by destaining in 10% acetic acid and measuring absorbance of the solution at 560 nm.

### Apoptosis assays

To assess apoptosis, two separate assays were used.

TUNEL staining was performed by permeabilizing cells fixed on coverslips for 2min with 0.1% Triton X-100 in 0.1% sodium citrate, followed by labeling with 10% TUNEL enzyme versus label solution for 45min (Roche). Objective analysis of the percentage of TUNEL-positive cells was performed using CellProfiler software v2.3 by scoring the # of TUNEL positive objects filtered over DAPI-positive objects (Nuclei). Only TUNEL positive objects were considered that were also DAPI positive.

For the Cytochrome-C release assay, cells were seeded on coverslips in a 24-well plate and incubated for 5d total with the pan-caspase-inhibitor QVD-OPH (20  $\mu$ M in 500 $\mu$ l). The media was refreshed on day 3. Subsequently, the cells were processed for Cytochrome-C positivity by immunofluorescence. We measured the percentage of cells that showed a mitochondrial release of mitochondrial Cytochrome-C, identified either as diffuse staining, or complete absence.

### Real-time cell density assay

Real-time cell density was measured using an xCELLigence detection system (ACEA Biosciences). Prior to the measurement, 50  $\mu$ l DMEM 10% FCS was added to each well of an E-plate view 16 (Roche) to establish background signal. Non-senescent (2000 cells per well) and senescent (5000 cells/well) IMR90 fibroblasts were then plated in 150  $\mu$ l medium. 16h later the E-plate was placed in the xCELLigence reader and the cell density was recorded every 30min. The cells were treated with 25 $\mu$ M FOXO4 peptide 8h after starting the measurements. Measurements continued for the indicated intervals.

### Real-time imaging of Caspase-3/7 activation

Cells were plated in 4-well Poly-L-Lysine coated glass bottom 35mm dishes (D141410; Matsumi, Japan) and incubated with NucView488 Caspase-3 (4440; Essen Bioscience). FOXO4-DRI or PBS was added and the cells were transferred to a Heat and CO<sub>2</sub>-controlled incubator, attached to a LSM510 confocal microscope (Zeiss). 8h after addition, real-time imaging was initiated and every 30min a grid of 3x3 pictures was recorded. The imaging continued for another 6 days and the images were concatenated using Zen imaging software (Zeiss; See Mov3+4).

### Genotyping of mice

For PCR genotyping the following primers were used (See also [Table S1](#)):

For p16::3MR-1: p16::3MR1: 5'-AACGCAAACGCATGATCACTG-3' and p16::3MR-2: 5'-TCAGGGATGATGCATCTAGC-3'. Positive animals show a band at 202bp.  
For XpdTTD/TTD: p145: CCCGGCTAGAGTATCTGC, p184: GCCGGAATACGGGGCCA and p $\beta$ rev:TCTATGGTTAAGTTCATGTCATAGGAAGGGGAGAA.

### Design of mouse experiments

For the calculation of the estimated sample size a power analysis was performed according to the formula:  $n = 2(Z_{\alpha/2} + Z_{\beta})^2 * \sigma^2 / \Delta^2$ , with a power (1- $\beta$ ) of 80% and a significance ( $\alpha$ ) of 0.05. Prior to the study, pilot experiments were performed to determine the differences in plasma [Urea] of 26wk old wt versus Xpd<sup>TTD/TTD</sup> mice. This led to a  $\Delta$  and  $\sigma$  such that a sample size of 7 mice per group were estimated to be required to see differences in such experiments. This is shown in [Figure 6K](#). Later, it was found that sample sizes could be reduced when using mice of older age. This was applied in [Figure 6L](#) and [Figure 7](#). For other assays, no information on  $\Delta$  and  $\sigma$  was available and similar, or less stringent, sample sizes were deemed necessary. We only mice included mice that were of sufficient body weight at the start of the experiment, typically at least 80% of the average littermate weight of the same sex and genotype.

### Assessment of running wheel activity

For assessment of running wheel behavior, we only included mice which at baseline ran at least 0.1km/day. Running wheel activity was continuously measured and plotted in km/day. The mice were placed in running wheel cages with ample time to adjust and get trained in using the wheel. After withdrawal of a blood sample, the mice were allowed to recover for at least 1 day and the average running wheel activity over the next two days was taken as baseline value. The mice were subsequently treated with FOXO4-DRI, or PBS (Mock) and at  $t = 21$  d after baseline ( $t = 18$  d after 1<sup>st</sup> treatment) the average running wheel activity over 4 days was scored. The ratio of mice of both sexes from four independent experiments was calculated and the % activity plotted in Figure 5I. Note that in some cases blood samples were taken at  $t = 9$  after treatment causing a temporary dip in activity.

### Fur density analysis

$Xpd^{TTD/TTD}$  mice show reduced fur density (de Boer et al., 2002; de Boer et al., 1998). To score any changes that might occur over time, the phenotype was ranged from 0-4 where 0 was very patched and 4 was wild-type. Each mouse was scored before and after the experiment as indicated in Figure 5C and Figure S5A. The final score was determined as the ratio (final-baseline)/baseline and the % change was subsequently plotted. Following several initial pilot observations, the experiment shown in Figure 5C contains mice from two independent cohorts. For naturally aged mice (Figure 7D), only males were included, since we did not observe significant hair loss in females. In these cohorts, 80% showed (varying degrees of) loss of hair at the beginning (115+ wks), or developed it over the course of the experiment.

### Infrared-measurements of abdominal temperature

From handling wt versus  $Xpd^{TTD/TTD}$  mice, there appeared to be a difference in surface temperature. This we reasoned to be caused by changes in fur density. To further quantify such changes, the abdominal temperature was subsequently measured using an infrared thermometer. Even though the variation in individual measurements per animal was relatively large,  $Xpd^{TTD/TTD}$  mice showed a significantly higher average infrared-measured abdominal temperature in general (See also Figure 5E). There were also mice with a relatively normal temperature. To assess the effect of FOXO4-DRI versus PBS therefore only mice with a baseline temperature  $> 34$  degrees were included as the window of visualizing any changes would otherwise be too small.

### Immunohistochemistry

For immunohistochemistry, paraffin sections of liver and intestine specimens were deparaffinized, rehydrated in decreasing concentrations of ethanol, treated for 10 min with 3%  $H_2O_2$  to quench endogenous peroxidase activity and heated to  $100^\circ C$  for 1 hr in 10 mM sodium citrate buffer, pH 6, for antigen retrieval. Subsequently the tissues were processed as for immunofluorescence. Paraffin embedded heart tissue was serially sectioned into  $5 \mu m$  slices, deparaffinized and rehydrated before Hematoxylin-Eosin (HE) staining or Picro Sirius Red staining was performed. For the HE staining, the sections were stained in Gills Hematoxylin (Sigma) for 4 min and 30 s in Eosin-Y solution. To stain for collagen, sections were incubated for 60 min in Picro Sirius Red solution (1g/L in picric acid) and briefly rinsed twice in 0.05% acetic acid.

### Bioluminescence

For in vivo luminescence, mice were injected i.p. with 15 mg of Xenolight RediJect Coelenterazine (Caliper). 20 min later, the mice were anesthetized (2%–4% isoflurane) and placed in a dorsal position during imaging. Bioluminescence was measured with a Xenogen IVIS-200 Optical in vivo imaging System (Caliper Life Sciences; 5 min exposure). Photon flux was quantified within a circular region of interest (ROI) encompassing the site of substrate injection and the total radiance was corrected for time and surface area measured.

### Plasma values as measure for tissue function

On the indicated time points, whole blood samples were collected in a Microvette with Lithium Heparin (Sarstedt) for plasma separation and spun for 10min at  $4.6 \times g$ . The (clear) supernatant was transferred into regular 1.5ml tubes and spun again for 5min at  $4.6 \times g$ . The supernatants were transferred again into 1.5ml tubes, snap frozen in liquid  $N_2$  and stored at  $-80^\circ C$ . [AST] was measured using an AST Activity Assay Kit (Sigma). The samples were incubated with 100 $\mu l$  reaction mix in a 96 well plate and placed at  $37^\circ C$ . The absorbance at 450nm was determined after 2 min for baseline analysis and after 40 min for a final analysis. [Urea] was measured using a QuantiChrom Urea Assay Kit (Gentaur). The samples were incubated in 200 $\mu l$  reaction mix for 10 min at room temperature before absorbance was measured at 520nm. [Creatinine] was measured using Creatinine Assay Kit (Sigma). Samples were incubated with 50 $\mu l$  reaction mix at  $37^\circ C$  for 60 min and the absorbance was measured at 570nm. Ratios comparing plasma values after treatment compared to baseline were determined and plotted as % over baseline in scatterplots.

### Post mortem SA- $\beta$ -GAL assay

All tissues were flash frozen in Optimal Cutting Temperature (OCT) Tissue Tek and stored until ready for processing. Subsequently, 10  $\mu m$  slices were cryosectioned and placed on charged microscopy slides. These were washed with ice-cold PBS for 5min and fixed in formalin for 15min on ice. Immediately after fixation the samples were washed once briefly with MilliQ and stained overnight at  $37^\circ C$  with fresh SA- $\beta$ -GAL solution (pH 6.0), containing 2,5 mM  $Na_2HPO_4$ , 7,4 mM Citric Acid, 0.15M NaCl, 2mM  $MgCl_2$ , 5 mM Potassium

Ferricyanide, 5 mM Potassium Ferrocyanide and 25ul/ml 4% X-gal in DMF. Samples were mounted using soft set mounting medium with DAPI (Vectashield) and sealed with nail polish. Cultured cells were treated similarly.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Unpaired Student's t tests were used to calculate the p value for pairwise comparisons. For multiple comparisons p values were calculated using one-way ANOVA with Bonferroni post-test correction (Graph-Pad Prism). For comparisons of fold change differences an unpaired one-tailed t test on the 2Log fold differences was applied. For the comparison of RLUC expression in naturally aged p16::3MR mice (Figure 7A) and the change in abdominal temperature (Figure 5E, right panel) a N-1 binary comparison test was performed. When averaging quantifications of single analyses, the "sum of squares"-rule was applied. The following indications of significance were used throughout the manuscript: \*  $p < 0.05$ , \*\*  $p < 0.01$ .

### DATA AND SOFTWARE AVAILABILITY


The RNA-Seq data obtained in this study has been uploaded to NCBI GEO datasets, under accession number GSE94395 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94395>).

The software to analyze the data is available at <http://rna-ome.erasmusmc.nl/>.


A

Name	Ctrl	Sen	F.C.	p-value
TP53INP1			2.83	1.06E-80
TP53			1.55	4.78E-17
PUMA			2.59	5.06E-26
BIM			3.56	4.55E-12
lBID			1.31	5.19E-08
BAD			1.17	8.71E-04
NOXA			-1.20	6.98E-03
Survivin			-12.95	0.00E+00
BCL2			-5.00	4.25E-19
BCL-XL			-1.13	8.80E-03
MCL1			1.03	4.35E-01
BCL-W			1.20	8.64E-05
BAK			1.01	8.83E-01
BAX			1.17	1.91E-03
Cytochrome C			1.04	3.53E-01
SMAC			1.11	2.53E-02
XIAP			1.16	7.07E-03
APAF1			-1.46	6.57E-10
Caspase-9			1.48	2.45E-05
Caspase-3			1.22	7.22E-05
Caspase-6			-1.42	6.23E-06
Caspase-7			-1.03	9.33E-01
FADD			-1.22	1.30E-04
TRADD			1.16	1.77E-02
Caspase-8			1.42	2.37E-05

Difference in mRNA expression vs. average between groups



C



B

Name	Full name	Fold change	p-value
E2F2	E2F transcription factor 2	0.11	9.32E-33
E2F1	E2F transcription factor 1	0.16	9.83E-173
FOS	FBJ murine osteosarcoma viral oncogene homolog	0.48	2.07E-07
IRF6	interferon regulatory factor 6	0.59	7.93E-02
E2F3	E2F transcription factor 3	0.61	4.69E-20
FOSB	FBJ murine osteosarcoma viral oncogene homolog B	0.62	1.84E-02
STAT5B	signal transducer and activator of transcription 5B	0.62	6.86E-23
MSX1	msh homeobox 1	0.65	5.60E-03
STAT5A	signal transducer and activator of transcription 5A	0.74	2.33E-06
E2F4	E2F transcription factor 4, p107/p130-binding	0.87	2.95E-03
RELA	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	0.89	4.65E-03
JUNB	jun B proto-oncogene	0.99	9.44E-01
MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	1.09	8.34E-02
NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	1.17	2.22E-04
FOXO3	forkhead box O3	1.22	3.01E-05
MAX	MYC associated factor X	1.28	5.99E-07
IRF9	interferon regulatory factor 9	1.34	7.00E-08
TRPS1	trichorhinophalangeal syndrome I	1.36	7.50E-06
JUND	jun D proto-oncogene	1.47	4.65E-14
STAT3	signal transducer and activator of transcription 3 (acute-phase response factor)	1.49	5.23E-20
STAT6	signal transducer and activator of transcription 6, interleukin-4 induced	1.50	6.90E-22
TP53	tumor protein p53	1.55	4.78E-17
STAT1	signal transducer and activator of transcription 1, 91kDa	1.76	1.51E-40
STAT2	signal transducer and activator of transcription 2, 113kDa	1.80	9.54E-46
NFKB2	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)	1.81	9.62E-44
FOXO4	forkhead box O4	1.94	2.52E-13
RELB	v-rel reticuloendotheliosis viral oncogene homolog B	2.12	1.07E-37
STAT4	signal transducer and activator of transcription 4	3.32	9.35E-08

(legend on next page)

---

**Figure S1. Related to Figure 1**


(A) Table showing color-coded changes in mRNA expression, fold change (FC) and *p* values of the indicated apoptosis-associated genes in senescent versus control IMR90. This figure is complementary to [Figure 1A](#) showing the cell-intrinsic apoptosis pathway.

(B) Table showing the fold change and *p* values of apoptosis-associated transcriptional regulators with FOXO4 highlighted in green. This figure complements [Figure 1B](#), which shows a volcano plot of all transcriptional regulators.

(C) Treatment plan and visualization of cell density of senescent cells transduced with shRNAs against FOXO4. This figure is complementary to [Figure 1H](#).








**Figure S3. Related to Figure 3**

(A) Viability assay on control IMR90, BJ, and WI-38 and counterparts induced to senescence by 10 Gy IR and incubated with FOXO4-DRI or PBS.

(B) Viability assays comparing the effects of the cocktail of quercetin (20  $\mu$ M) with increasing doses of dasatinib, ABT-737, or FOXO4-DRI when applied once on control or senescent IMR90.

(C) Treatment schedule for Figure 3E.

(D) Immunoblot determining the effect of two independent short hairpins against p53 on p53 expression. NIH 3T3 cells were transiently transfected with the indicated shRNAs used in Figure 3F in combination with pBABE-Puro. After 2 days' puromycin selection, the samples were processed for immunoblotting.



**Figure S4. Related to Figure 4**

(A) Schematic overview of the p16::3MR construct, which comprises the promoter of p16<sup>ink4a</sup> that drives expression of a trimodality reporter (3MR) consisting of Renilla luciferase (RLUC) for bioluminescence detection, RFP for fluorescence detection, and TK-HSV, which can be used to induce selective clearance using ganciclovir (GCV).

(B) Reduced but subsequent doses of FOXO4-DRI show to be more efficient in targeting doxorubicin-senescent IMR90, than one times high dose treatment. Senescent or doxo-senescent IMR90 cells were exposed one time to the final concentration of FOXO4-DRI, or three times 1/3 that dose. The SI75 was compared between both treatment regimes.

(C) Immunofluorescence for IL6 in control or doxo-senescent cells.

(D) Representative mice and quantification of p16-driven RLuc radiance in five mice i.p. injected with 10 mg/kg doxorubicin and analyzed on the indicated time-points.

(E) Visualization of change in doxorubicin-induced p16-mediated senescence through bioluminescence in mice treated as in Figure 4I, but with five times 25 mg/kg i.p. GCV (days 1,2,3,4, and 5) for semigenetic clearance of senescence or the same regimen in addition to three times IV 5 mg/kg FOXO4-DRI (days 1,3, and 5).


(F) Quantification of the % AST in plasma of mice from Figure S4E after treatment versus baseline.



**Figure S5. Related to Figure 5**

(A) Overview of the fur status of the indicated XpdTTD/TTD mice before or after treatment with PBS (left columns) or FOXO4-DRI (right columns), respectively. The mice were scored 0–4 where 4 is fur as seen in wild-type mice and 0 is most reduced. The % change was calculated for each mouse and plotted in Figure 5D. Red arrows indicate deterioration of the indicated area over time, whereas green arrows indicate improvement.

(B) Example of difference in behavior of XpdTTD/TTD mice treated with PBS or FOXO4-DRI. To address this more quantitatively, the responsiveness to gentle stimuli was measured as described in Figure 5F.



**Figure S6. Related to Figure 6**

(A) Schematic overview of kidney slice culture experiment and subsequent analysis. Fresh kidneys were isolated and sectioned in 200  $\mu$ m slices. These were placed in 24-well plate wells in tissue culture medium while rotating at 60 rpm (See also [Kruiswijk et al., 2016](#)). Following treatment with shRNAs the slices were processed for TUNEL staining, and the percentage positive cells were objectively scored.

(B) Treatment plan for kidney slice experiments in [Figure 6E](#) and [Figures S6C–S6D](#).


(C) Example of shGFP and shFOXO4 (mouse) transduced 130-week WT kidney slices stained for TUNEL (left), segmented for DAPI (middle), and scored for percentage TUNEL positive (right) using CellProfiler V2.3.

(D) Quantification of  $n = 6$  kidney slices processed as in (C).

(E) Whole blood analysis of the mice in [Figure 6F](#).

(F) Heart sections of PBS- or FOXO4-DRI-treated wt mice (26 weeks), stained by H&E for general pathology, and Picro Sirius Red to visualize collagen deposition.  $N > 4$ . No apparent abnormalities were observed.

(G) FOXO4-DRI does not significantly alter total body weight, nor kidney weight (normalized to total body weight) of WT or XpdTTD/TTD mice. This figure complements [Figures 6G, 6J, 6K, and 6L](#) by showing that, while FOXO4-DRI does not influence total kidney mass, it does improve renal function.



**Figure S7. Related to Figure 7**

(A) Quantitative representation of the % p16-driven senescence (RLUC) in naturally aged mice treated with FOXO4-DRI or PBS. Note the large biological spread in signal.

(B) Overview of the fur status of the indicated naturally aged mice before or after treatment with PBS (left columns) or FOXO4-DRI (right columns), respectively. Right panel: quantification of the % change as also described in Figure 5D.

(C) Quantification of the % change in body weight of naturally aged mice treated as in Figures 7B–7I (left panel) or Figure 7J (right panel).